敗血症　感染症と臓器障害への対応

出版社： 中山書店
著者：
発行日： 2023-01-20
分野： 臨床医学：一般  >  救命/救急
ISBN： 9784521743363
電子書籍版： 2023-01-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

敗血症の原因となるさまざまな細菌やウイルスなどによる感染症の管理と，敗血症によって引き起こされる敗血症性ショックなどの臓器障害の管理について解説．
抗菌薬のTDM，血液浄化法などの敗血症を管理するための工夫を取り上げ，「日本版敗血症診療ガイドライン」やCOVID-19についても盛り込んだ．
敗血症をより深く理解して，どのような病態にも対応できる，これからの敗血症診療を見据える一冊．

目次

  • 1章　総論
    　1-1　敗血症の歴史
    　1-2　感染症の歴史
    　1-3　敗血症の病態生理
    　1-4　感染症における自然免疫

    2章　敗血症と感染症の診断
    　2-1　敗血症の定義と診断
    　2-2　感染症疾患の定義と診断
    　2-3　細菌診断におけるグラム染色
    　2-4　微生物診断における特殊検査
    　2-5　感染症と敗血症のバイオマーカー

    3章　感染症の管理
    　［3-1　総論］
    　3-1-1　院内感染で注意するべき微生物
    　3-1-2　細菌培養検査/薬剤感受性の適正評価
    　3-1-3　ドレーンを用いた感染症管理
    　［3-2　各論］
    　3-2-1　ブドウ球菌属：MSSA，MRSA，MRCNS
    　3-2-2　エンテロコッカス属
    　3-2-3　クレブシエラ属
    　3-2-4　アシネトバクター属
    　3-2-5　緑膿菌
    　3-2-6　エンテロバクター属
    　3-2-7　大腸菌
    　3-2-8　結核菌
    　3-2-9　肺炎球菌
    　3-2-10　溶血性レンサ球菌
    　3-2-11　レジオネラ属
    　3-2-12　クロストリジウム属
    　3-2-13　ウイルス感染症：COVID-19を念頭においた対応
    　3-2-14　深在性真菌症
    　3-2-15　ダニ媒介感染症

    4章　ベーシック：敗血症性臓器障害の管理
    　4-1　日本版敗血症診療ガイドライン
    　4-2　モニタリング
    　4-3　鎮痛・鎮静・せん妄・睡眠の管理
    　4-4　ARDSの病態と管理
    　4-5　敗血症性ショックの管理：血管障害と心臓障害
    　4-6　急性腎障害の管理
    　4-7　播種性血管内凝固の管理
    　4-8　神経・筋障害の管理：PICS への対応
    　4-9　急性期栄養管理
    　4-10　電解質/内分泌の管理
    　4-11　臨床工学機器の管理
    　4-12　早期リハビリテーションの実際

    5章　アドバンス：敗血症管理の工夫
    　5-1　災害時における感染症と敗血症への対応
    　5-2　敗血症の早期発見のためのシステム
    　5-3　抗菌薬のTDMの工夫
    　5-4　敗血症における神経集中治療
    　5-5　敗血症における人工呼吸管理の工夫
    　5-6　敗血症におけるβ遮断薬の適正使用法
    　5-7　敗血症における血液浄化法の工夫
    　5-8　ステロイド療法の工夫
    　5-9　経腸栄養管理の工夫
    　5-10　ビタミン投与の評価と検討

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 総論

P.20 掲載の参考文献
1) Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
 
2) Levy MM, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
PubMed
3) Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:801-10.
PubMed
4) Bone RC, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
PubMed
5) Bone RC, et al. Sepsis syndrome:A valid clinical entity. Crit Care Med 1989;17:389-93.
PubMed
6) Vincent JL, et al. Sepsis definitions:Time for change. Lancet 2013;381:774-5.
PubMed
7) Kaukonen KM, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015;372:1629-38.
PubMed
8) Seymour CW, et al. Assessment of clinical criteria for sepsis:For the Third International Consensus Definition for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:762-74.
PubMed
9) Shanker-Hari M, et al. Developing new definition and assessing new clinical criteria for septic shock:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:775-87.
 
10) 丸藤 哲. Sepsisの定義および診断基準の歴史的変遷. Thromb Med 2018;8:57-62.
Medical*Online
11) 丸藤 哲. SIRSとqSOFAの意義. Thromb Med 2021;11:71-6.
Medical*Online
12) Rangel-Flausto MS, et al. The natural history of the systemic inflammatory response syndrome(SIRS). A prospective study. JAMA 1995;273:117-23.
 
13) Herwanto V, et al. Accuracy of quick sequential organ failure assessment score to predict sepsis mortality in 121 studies including 1, 716, 017 individuals:A systematic review and meta-analysis. Crit Care Explor 2019;1:e0043.
PubMed
14) Evans L, et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021;49:e1063-143.
PubMed
15) Levy MM, et al. Surviving sepsis campaign:Association between performance metrics and outcomes in a 7. 5-year study. Crit Care Med 2015;43:3-12.
 
16) Wang HE, et al. Revised national estimates of emergency department visit for sepsis in the United States. Crit Care Med 2017;45:1443-9.
 
17) Esmon CT, et al. Inflammation, sepsis, and coagulation. Haematologica 1999;84:254-9.
PubMed
18) Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34-45.
PubMed
19) Gando S, et al. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016;2:16037.
PubMed
20) Society of Critical Care Medicine. Surviving Sepsis Campaign Declarations. 'Barcelona Declaration' Aims to Tackle 10th Most Common Cause of Death. https://www.sccm.org/SurvivingSepsisCampaign/About-SSC/History/Barcelona-Declaration
 
21) Dellinger RP, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
PubMed
P.29 掲載の参考文献
1) 茨木 保. 顕微鏡の発明. まんが 医学の歴史. 東京:医学書院;2008. p.68-85.
 
2) 坂井建雄. 図説 医学の歴史. 東京:医学書院;2019. p.229-32.
 
3) Hershkovitz I, et al. Detection and molecular characterization of 9, 000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLos One 2008;3:e3426.
 
4) 石 弘之. 図解 感染症の世界史. 東京:株式会社KADOKAWA;2021. p.20-1.
 
5) 金原正子. 埋葬人骨の寄生虫卵分析. 富山県文化振興財団埋蔵文化財調査事務所, 編. 小竹貝塚発掘調査報告. 富山:富山県文化振興財団埋蔵文化財調査事務所;2014. p.2-10.
 
6) Hawass Z, et al. Ancestry and pathology in King Tutankhamun's family. JAMA 2010;303:638-47.
PubMed
7) Iuliano AD, et al. Estimates of global seasonal influenza-associated respiratory mortality:A modelling study. Lancet 2018;391:1285-300.
PubMed
8) van Thiel PH, et al. A nematode parasitic to herring, causing acute abdominal syndromes in man. Trop Geogr Med 1960;12:97-113.
 
9) 厚生労働省エイズ動向委員会. 令和2(2020)年エイズ発生動向-概要. https://api-net.jfap.or.jp/status/japan/data/2020/nenpo/r02gaiyo.pdf(2022年7月18日閲覧)
 
10) Nicholas LePan. Visualizing the History of Pandemic. https://www.visualcapitalist.com/history-of-pandemics-deadliest/(2022年7月18日閲覧)
 
11) 加藤茂孝. 人類と感染症の歴史-未知なる恐怖を超えて. 東京:丸善出版;2013. p.32-40.
 
12) 大村敏郎. ペスト. 嶋田甚五郎, ほか編. 感染症-人類を悩ませてきた病. 東京:第一製薬株式会社;1998. p.56-57.
 
13) 坂井建雄. 図説 医学の歴史. 東京:医学書院;2019. p.260-263.
 
14) Zborowsky T. The legacy of Florence Nightingale's environmental theory:Nursing research focusing on the impact of healthcare environments. HERD 2014;7:19-34.
 
15) Morens DM, et al. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza:Implications for pandemic influenza preparedness. J Infect Dis 2008;198:962-70.
PubMed
16) ミーラ・センティリンガム. 人類は感染症とともに生きていく-学校では教えてくれないパンデミックとワクチンの現代史. 東京:羊土社;2020. p.86-93.
 
17) RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704.
 
18) 国立研究開発法人 国立国際医療研究センター AMR臨床リファレンスセンター. 全国抗菌薬販売量サーベイランス. 2013-2021. https://amrcrc.ncgm.go.jp/surveillance/020/file/Sales_2013-2021_2.pdf(2022年7月23日閲覧)
 
19) 福島靖正. 検疫法の変遷と新型コロナウイルス感染症の経験を踏まえた今後の対応. 公衆衛生 2021;85:239-43.
 
20) 厚生労働省検疫所FORTH. マラリアについて(ファクトシート). https://www.forth.go.jp/moreinfo/topics/20190628.html(2022年7月23日閲覧)
 
21) 厚生労働省検疫所FORTH. エボラウイルス病について(ファクトシート). https://www.forth.go.jp/moreinfo/topics/20190729.html(2022年7月23日閲覧)
 
22) 門村将太. 抗菌薬供給不足が発生したとき, 現場で何を考え, どう動くか. 薬局2021;72:17-22.
 
P.40 掲載の参考文献
1) Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
 
2) Singer M, et al. The third international consensus definitions for sepsis and septic shock(Sepsis-3). JAMA 2016;315:801-10.
PubMed
3) 平澤博之. PAMPs, alarmins, DAMPs. 栄養-評価と治療 2015;32:42-5.
Medical*Online
4) 平澤博之. 敗血症の病態生理とcytokine-adsorbing hemofilter-CHDFを用いたその制御-up-to-date 2011. 日本急性血液浄化学会雑誌 2011;2:143-51.
Medical*Online
5) 平澤博之. 敗血症の病態生理と診療の最近の話題. 日腹部救急医会誌 2014;34:815-22.
 
6) Timmermans K, et al. Danger in the intensive care unit:DAMPS in critically ill patients. Shock 2016;45:108-16.
PubMed
7) Harris HE, et al. Alarmin(g)news about danger:Workshop on innate danger signals and HMGB1. EMBO Rep 2006;7:774-8.
PubMed
8) Lubkin DT, et al. Extracellular mitochondrial DNA and N-formyl peptides in trauma and critical illness:A systematic review. Crit Care Med 2018;46:2018-28.
 
9) Hu Q, et al. The role of mitochondrial DNA in the development of ischemia reperfusion injury. Shock 2019;51:52-9.
PubMed
10) 平澤博之. 敗血症の今日的病態生理におけるエンドトキシンの位置づけとPMX-DHPの意義. ICUとCCU 2020;44:541-8.
Medical*Online
11) Opal SM, et al. Effect of Eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis:The ACCESS randomized trial. JAMA 2013;309:1154-62.
PubMed
12) Dellinger RP, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level:The EUPHRATES randomized clinical trial. JAMA 2018;320:1455-63.
PubMed
13) Matsumoto N, et al. Interleukin-8 induces an elevation in the endotoxin activity assay (EAA)level:Does the EAA truly measure the endotoxin level? J Infect Chemother 2013;19:825-32.
 
14) Vincent J-L, et al. Sepsis definitions:Time for change. Lancet 2013;381:774-5.
PubMed
15) Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020;383:2255-73.
PubMed
16) Ge Q, et al. Modulatory mechanisms of NLRP3:Potential roles in inflammasome activation. Life Sci 2021;267:118918.
PubMed
17) 平澤博之. 敗血症の病態生理におけるhypercytokinemia とendothelial hyperpermeability. ICUとCCU 2016;40:635-43,
Medical*Online
18) Boomer JS, et al. The changing immune system in sepsis:Is individualized immuno-modulatory therapy the answer? Virulence 2014;5:45-56.
PubMed
19) Cecconi M, et al. Sepsis and septic shock. Lancet 2018;392:75-87.
PubMed
20) Hotchkiss R, et al. The sepsis seesaw:Tilting toward immunosuppression. Nat Med 2009;15:496-7.
PubMed
21) Xiao W, et al. A genomic storm in critically injured humans. J Exp Med 2011;208:2581-90.
 
22) Urban C, Zychlinsky A. Netting bacteria in sepsis. Nat Med 2007;13:403-4.
PubMed
23) Angus DC, et al. Severe sepsis and septic shock. N Engl J Med 2013;369:840-51.
PubMed
24) Krezalek MA, et al. The sift of an intestinal "microbiome" to a "pathobiome" governs the course and outcome of sepsis following surgical injury. Shock 2016;45:475-82.
 
25) Papayannopoulos V, et al. NETs:A new strategy for using old weapons. Trends Immunol 2009;30:513-21.
PubMed
26) Camicia G, et al. Neutrophil extracellular traps in sepsis. Shock 2014;42:286-94.
PubMed
27) Petretto A, et al. Neutrophil extracellular traps(NET)induced by different stimuli:A comprehensive proteomic analysis. PLoS One 2019;14:e0218946.
 
28) Ueno H, et al. Coagulation/fibrinolysis abnormality and vascular endothelial change in the pathogenesis of thrombocytopenic multiple organ failure. Crit Care Med 2002;30:2242-8.
 
29) Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 2010;363:689-91.
PubMed
30) 平澤博之, ほか. 侵襲時の血管内皮透過性亢進の病態生理と輸液療法に与える影響およびその対策. ICUとCCU 2014;38:719-26.
Medical*Online
31) Tapia P, et al. Circulating endothelial cells from septic shock patients convert to fibroblasts are associated with the resuscitation fluid dose and are biomarkers for survival prediction. Crit Care Med 2019;47:942-50.
PubMed
32) Li H, et al. SARS-CoV-2 and viral sepsis:Observations and hypotheses. Lancet 2020;395:1517-20.
PubMed
33) Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020;383:120-8.
PubMed
34) Chignalia AZ, et al. The glycocalyx and trauma:A review. Shock 2016;45:338-48.
PubMed
35) Oami T, Coopersmith CM. Measurement of intestinal permeability during sepsis. Methods Mol Biol 2021;2312:169-75.
 
36) Rosenbaum JT, Silverman GJ. The microbiome and systemic lupus erythematosus. N Engl J Med 2018;378:2236-7.
PubMed
37) Habes QLM, et al. Markers of intestinal damage and their relation to cytokine levels in cardiac surgery patients. Shock 2017;47:709-14.
PubMed
38) Hotchkiss RS, et al. Cell death. N Engl J Med 2009;361:1570-83.
PubMed
39) Watanabe E, et al. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleujkin-1-related gene polymorphisms. Crit Care Med 2005;33:89-97.
PubMed
40) Watanabe E, et al. Tumor necrosis factor-308 polymorphism(rs1800629)is associated with mortality and ventilator duration in 1057 Caucasian patients. Cytokine 2012;60:249-56.
PubMed
41) Seymour CW, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes of sepsis. JAMA 2019;321:2003-17.
PubMed
42) Bhatraju PK, et al. Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy. Am J Respir Crit Care Med 2019;199:863-72.
PubMed
43) Sugeir S, Naylor S. Critical care and personalized or precision medicine. Who needs whom? J Crit Care 2018;483:401-5.
PubMed
44) Newton-Cheh C, et al. Case 24-2020:A 44-year-old woman with chest pain, dyspnea, and shock. N Engl J Med 2020;383:475-84.
 
45) Sinha P, et al. Is a "cytokine storm" relevant to COVID-19? JAMA Int Med 2020;180:1152-4.
 
46) Shappell CN, et al. Does severe acute respiratory coronavirus 2 cause sepsis? Crit Care Med 2020;48:1707-9.
PubMed
47) Osuchowski MF, et al. COVID-19:Pathophysiology of acute disease 1. The COVID-19 puzzle:Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021;9:622-42.
PubMed
48) The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 2021;384:1491-502.
PubMed
49) Buckley LF, et al. Role for anti-cytokine therapies in severe coronavirus disease 2019. Crit Care Expl 2020;2:e0178.
 
50) Remy KE, et al. Immuonotherapy for COVID-19:Lessons learned from sepsis. Lancet Respir Med 2020;8:946-9.
PubMed
P.57 掲載の参考文献
1) Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20.
PubMed
2) Iwasaki H, et al. The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol 2011;12:1167-75.
 
3) Swanson KV, et al. The NLRP3 inflammasome:Molecular activation and regulation to therapeutics. Nat Rev Immunol 2019;19:477-89.
 
4) Rehwinkel J, Gack MU. RIG-I-like receptors:Their regulation and roles in RNA sensing. Nat Rev Immunol 2020;20:537-51.
PubMed
5) Motwani M, et al. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet 2019;20(11):657-74.
PubMed
6) Takahashi A, et al. Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat Commun 2018;9:1249.
PubMed
7) Kujirai T, et al. Structural basis for the inhibition of cGAS by nucleosomes. Science 2020;370:455-8.
PubMed
8) Miyake Y, et al. C-type lectin MCL is an FcRγ-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity 2013;38:1050-62.
 
9) Pardi N, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17:261-79.
PubMed
10) Andries O, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release 2015;217:337-44.
PubMed

2章 敗血症と感染症の診断

P.68 掲載の参考文献
1) Seymour CW, et al. Assessment of Clinical Criteria for Sepsis:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:762-74.
PubMed
2) Geroulanos S, Douka ET. Historical perspective of the word "sepsis". Intensive Care Med 2006;32:2077.
PubMed
3) Budelmann G. Hugo Schottmuller, 1867-1936. The problem of sepsis. Internist(Berl) 1969;10:92-101.
PubMed
4) Bone RC, et al. Sepsis syndrome:A valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989;17:389-93.
 
5) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
PubMed
6) Levy MM, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
PubMed
7) Kaukonen KM, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16.
PubMed
8) Churpek MM, et al. Incidence and prognostic value of the systemic inflammatory response syndrome and organ dysfunctions in ward patients. Am J Respir Crit Care Med 2015;192:958-64.
PubMed
9) Kaukonen KM, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015;372:1629-38.
PubMed
10) Vincent JL, et al. Sepsis definitions:Time for change. Lancet 2013;381:774-5.
PubMed
11) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン 2020 特別委員会. 日本版敗血症診療ガイドライン 2020. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic shock 2020(J-SSCG2020). 日集中医誌 2021;28:S1-411.
 
12) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン 2020 特別委員会. 日本版敗血症診療ガイドライン 2020. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic shock 2020(J-SSCG2020). 日救急医会誌 2021;32:S1-411.
 
13) Vincent JL, et al. The SOFA(Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
 
14) Raith EP, et al. Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. JAMA 2017;317:290-300.
 
15) Freund Y, et al. Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department. JAMA 2017;317:301-8.
 
16) Fang X, et al. Clinical Evaluation of Sepsis-1 and Sepsis-3 in the ICU. Chest 2018;153:1169-76.
PubMed
17) Umemura Y, et al. Assessment of mortality by qSOFA in patients with sepsis outside ICU:A post hoc subgroup analysis by the Japanese Association for Acute Medicine Sepsis Registry Study Group. J Infect Chemother 2017;23:757-62.
 
18) Umemura Y, et al. Prognostic Accuracy of Quick SOFA is different according to the severity of illness in infectious patients. J Infect Chemother 2019;25:943-9.
 
19) Gando S, et al. The SIRS criteria have better performance for predicting infection than qSOFA scores in the emergency department. Sci Rep 2020 May 15;10:8095.
PubMed
20) Vincent JL, et al. qSOFA does not replace SIRS in the definition of sepsis. Crit Care 2016;20:210.
PubMed
21) Rhodes A, et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2016. Crit Care Med 2017;45:486-552.
PubMed
P.75 掲載の参考文献
1) Lammas DA, et al. Heterogeneity in the granulomatous response to mycobacterial infection in patients with defined genetic mutations in the interleukin 12-dependent interferon-gamma production pathway. Int J Exp Pathol 2002;83:1-20.
PubMed
2) Fujita J, et al. HRCT shows variations in appearance in disseminated tuberculosis in adults. Int J Tuberc Lung Dis 2006;10:222-6.
PubMed
3) Tokuda Y, et al. The degree of chills for risk of bacteremia in acute febrile illness. Am J Med 2005;118:1417.
PubMed
4) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会(編). 成人肺炎診療ガイドライン2017. 東京:日本呼吸器学会;2017.
 
P.84 掲載の参考文献
1) Geckler RW, et al. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol 1977;6:396-9.
PubMed
2) Hamaguchi S, et al. Neutrophil extracellular traps in bronchial aspirates:A quantitative analysis. Eur Respir J 2014;43:1709-18.
PubMed
3) Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5.
PubMed
4) Matsushima A, et al. Preemptive antibiotic treatment based on gram staining reduced the incidence of ARDS in mechanically ventilated patients. J Trauma 2008;65:309-15.
PubMed
5) Yoshimura J, et al. Impact of Gram stain results on initial treatment selection in patients with ventilator-associated pneumonia:A retrospective analysis of two treatment algorithms. Crit Care 2017;21:156.
PubMed
P.93 掲載の参考文献
1) Dominguez J, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001;119:243-9.
PubMed
2) Camou F, et al. Usefulness of pneumococcal antigen urinary testing in the intensive care unit? Med Mal Infect 2015;45:318-23.
PubMed
3) 吉田佳成子, ほか. 肺炎球菌尿中抗原検出キットを用いた尿中抗原陽性持続時間についての検討. 日呼吸会誌 2003;41:521-5.
 
4) 村上日菜子, ほか. レジオネラ尿中抗原検出キットの比較検討-リボソームタンパク質L7/L12を検出する新規キットを含めて. 日本臨床微生物学会雑誌 2020;30:31-4.
 
5) Sopena N, et al. Factors related to persistence of Legionella urinary antigen excretion in patients with legionnaires' disease. Eur J Clin Microbiol Infect Dis 2002;21:845-8.
PubMed
6) Mitton B, et al. Laboratory evaluation of the BioFire FilmArray Pneumonia plus panel compared to conventional methods for the identification of bacteria in lower respiratory tract specimens:A prospective cross-sectional study from South Africa. Diagn Microbiol Infect Dis 2021;99:115236.
PubMed
7) Buchan BW, et al. Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections. J Clin Microbiol 2020;58:e00135-20.
PubMed
8) Gilbert DN, et al. Enhanced Detection of Community-Acquired Pneumonia Pathogens with the BioFire(R) Pneumonia FilmArray(R) Panel. Diagn Microbiol Infect Dis 2021;99:115246.
 
9) Hou TY, et al. Current status of MALDI-TOF mass spectrometry in clinical microbiology. J Food Drug Anal 2019;27:404-14.
PubMed
10) Tsuchida S, et al. An in-house centrifugation and membrane filtration technique for identifying microorganisms from positive blood culture bottles with high identification rates using matrix-assisted laser desorption ionization-Time-of-flight mass spectrometry:A preliminary report. J Infect Chemother 2020;26:266-71.
 
11) Nomura F, et al. Mass spectrometry-based microbiological testing for blood stream infection. Clin Proteomics 2020;17:14.
PubMed
12) Beganovic M, et al. Effect of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS)Alone versus MALDI-TOF MS Combined with Real-Time Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures. J Clin Microbiol 2017;55:1437-45.
PubMed
13) 松井秀仁, 花木秀明. MRSA のPBP2'を血液培養液から検出可能な「Qライン極東(R)PBP2'」のキットの評価. 医学と薬学 2020;77:1459-66.
 
14) 田中真輝人, ほか. MRSA-LAを用いる血液培養陽性ボトルからの直接迅速MRSA検出法の検討. 医学検査 2021;70:325-9.
Medical*Online
15) Seco MBS, et al. Improved blood culture workflow for faster identification of KPC-producing Enterobacterales. Braz J Microbiol 2019;50:127-32.
 
16) 松山由美子. MALDI-TOF MSによる微生物分析-同定を超えた最新技術. 電気泳動 2017;61:152-4.
Medical*Online
P.101 掲載の参考文献
1) Opal SM, Wittebole X. Biomarkers of Infection and Sepsis. Crit Care Clin 2020;36:11-22.
PubMed
2) Cavallazzi R, et al. Is the band count useful in the diagnosis of infection ? An accuracy study in critically ill patients. J Intensive Care Med 2010;25:353-7.
PubMed
3) Lai NA, Kruger P. The predictive ability of a weighted systemic inflammatory response syndrome score for microbiologically confirmed infection in hospitalised patients with suspected sepsis. Crit Care Resusc 2011;13:146-50.
PubMed
4) Mare TA, et al. The diagnostic and prognostic significance of monitoring blood levels of immature neutrophils in patients with systemic inflammation. Crit Care 2015;19:57.
 
5) Seebach JD, et al. The diagnostic value of the neutrophil left shift in predicting inflammatory and infectious disease. Am J Clin Pathol 1997;107:582-91.
PubMed
6) Ljungstrom L, et al. Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. PLoS One 2017;20:e0181704.
 
7) Ho KM, Lipman J. An update on C-reactive protein for intensivists. Anaesth Intensive Care 2009;37:234-41.
 
8) Tan M, et al. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis:A systematic review and meta-analysis. J Cell Biochem 2019;120:5852-9.
 
9) Simon L, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection:A systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17.
 
10) Kapasi AJ, et al. Host biomarkers for distinguishing bacterial from non-bacterial causes of acute febrile illness:A comprehensive review. PLoS One 2016;11:e0160278.
PubMed
11) Soraya GV, Ulhaq ZS. Crucial laboratory parameters in COVID-19 diagnosis and prognosis:An updated meta-analysis. Med Clin(Engl Ed) 2020;155:143-51.
PubMed
12) Povoa P, et al. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein:A prospective observational study. Crit Care 2006;10:R63.
PubMed
13) Wasserman A, et al. Septic patients presenting with apparently normal C-reactive protein:A point of caution for the ER physician. Medicine (Baltimore) 2019;98:e13989.
 
14) Lisboa T, et al. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med 2008;36:166-71.
 
15) Oliveira CF, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis:A randomized trial. Crit Care Med 2013;41:2336-43.
PubMed
16) Von Dach E, et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients with Uncomplicated Gram-Negative Bacteremia:A Randomized Clinical Trial. JAMA 2020;23:2160-9.
PubMed
17) Petel D, et al. Use of C-reactive protein to tailor antibiotic use:A systematic review and meta-analysis. BMJ Open 2018;8:e022133.
PubMed
18) Borges I, et al. Duration of antibiotic therapy in critically ill patients:A randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers. Crit Care 2020;24:281.
 
19) Vijayan AL, et al. Procalcitonin:A promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 2017;5:51.
PubMed
20) Jensen JU, et al. The Procalcitonin And Survival Study(PASS)- A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size(target population):1000 patients. BMC Infect Dis 2008;8:91.
 
21) Uzzan B, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma:A systematic review and meta-analysis. Crit Care Med 2006;34:1996-2003.
PubMed
22) Tang BMP, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients:Systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-7.
PubMed
23) Wacker C, et al. Procalcitonin as a diagnostic marker for sepsis:A systematic review and meta-analysis. Lancet Infect Dis 2013;13:426-35.
PubMed
24) Wu CC, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein:A systematic review and meta-analysis. Ann Intensive Care 2017;7:91.
 
25) Mann EA, et al. Use of procalcitonin for the detection of sepsis in the critically ill burn patient:A systematic review of the literature. Burns 2011;37:549-58.
 
26) Kamat IS, et al. Procalcitonin to distinguish viral from bacterial pneumonia:A systematic review and meta-analysis. Clin Infect Dis 2020;70:538-42.
PubMed
27) Jensen JU, et al;Procalcitonin And Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit:A randomized trial. Crit Care Med 2011;39:2048-58.
PubMed
28) Soni NJ, et al. Procalcitonin-guided antibiotic therapy:A systematic review and meta-analysis. J Hosp Med 2013;8:530-40.
PubMed
29) Matthaiou DK, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012;38:940-9.
PubMed
30) Wirz Y, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients:A patient-level meta-analysis of randomized trials. Crit Care 2018;22:191.
PubMed
31) Arulkumaran N, et al. Effect of Antibiotic Discontinuation Strategies on Mortality and Infectious Complications in Critically Ill Septic Patients:A Meta-Analysis and Trial Sequential Analysis. Crit Care Med 2020;48:757-64.
PubMed
32) Timsit JF, et al. Rationalizing antimicrobial therapy in the ICU:A narrative review. Intensive Care Med 2019;45:172-89.
PubMed
33) Chotiprasitsakul D, et al. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis 2018;66:172-7.
 
34) Kondo Y, et al. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients:A systematic review and meta-analysis. J Intensive Care 2019;7:22.
 
35) Pierrakos C, et al. Biomarkers of sepsis:Time for a reappraisal. Crit Care 2020;24:287.
PubMed
36) Maslove DM, et al. Validation of diagnostic gene sets to identify critically ill patients with sepsis. J Crit Care 2019;49:92-8.
PubMed
37) Fleuren LM, et al. Machine learning for the prediction of sepsis:A systematic review and meta-analysis of diagnostic test accuracy. Intensive Care Med 2020;46:383-400.
PubMed
38) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020(J-SSCG2020). 日集中医誌2021;28:S1-411.
 

3章 感染症の管理

P.112 掲載の参考文献
1) 厚生労働省. 院内感染対策サーベイランス事業(JANIS). https://janis.mhlw.go.jp/images/new/logotext.png
 
2) Kimmig A, et al. Management of Staphylococcus aureus Bloodstream Infections. Front Med(Lausanne) 2021;7:616524.
PubMed
3) Yamaguchi T, et al. Molecular Characterization of Community-Associated Methicillin-Resistant Staphylococcus aureus Isolated from Skin and Pus Samples of Outpatients in Japan. Microb Drug Resist 2015;21:441-7.
PubMed
4) Men P, et al. Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness:A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0146224.
PubMed
5) Aljefri DM, et al. Vancomycin Area Under the Curve and Acute Kidney Injury:A Meta-analysis. Clin Infect Dis 2019;69:1881-7.
PubMed
6) Shenoy ES, et al. Natural history of colonization with methicillin-resistant Staphylococcus aureus(MRSA)and vancomycin-resistant Enterococcus(VRE):A systematic review. BMC Infect Dis 2014;14:177.
 
7) Riley TV, Kimura T. The Epidemiology of Clostridium difficile Infection in Japan:A Systematic Review. Infect Dis Ther 2018;7:39-70.
PubMed
8) Durovic A, et al. New insights into transmission of Clostridium difficile infection-narrative review. Clin Microbiol Infect 2018;24:483-92.
PubMed
9) Nation RL, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis 2017;64:565-71.
PubMed
10) Nguyen M, Joshi SG. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections:A scientific review. J Appl Microbiol 2021. May 10. doi:10.1111/jam.15130
 
11) Ueda T, et al. Change in antimicrobial susceptibility of pathogens isolated from surgical site infections over the past decade in Japanese nation-wide surveillance study. J Infect Chemother 2021;27:931-9.
PubMed
P.119 掲載の参考文献
1) CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th Edition. CLSI M07, 2018.
 
1) Lee A, et al. Detection of bloodstream infections in adults:How many blood cultures are needed? J Clin Microbiol 2007;45:3546-8.
PubMed
2) CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 32nd Edition. CLSI M100-ED32, 2022. http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED32:2022&scope=user
 
3) CLSI. Principles and Procedures for Blood Cultures, 2nd Edition. CLSI M47-A2, 2022.
 
4) Baron EJ, et al. Cumitech 1c, Blood Cultures IV. Washington DC:ASM Press;2005.
 
P.128 掲載の参考文献
1) Wang Z, et al. Abdominal drainage versus no drainage post-gastrectomy for gastric cancer. Cochrane Database System Rev 2015;2015:CD008788.
 
2) Weindelmayer J, et al. Should we still use prophylactic drain in gastrectomy for cancer ? A systematic review and meta-analysis. Eur J Surg Oncol 2020;46:1396-1403.
 
3) Hoffmann J, et al. A prospective, controlled study of prophylactic drainage after colonic anastomoses. Dis Colon Rectum 1987;30:449-52.
 
4) Merad F, et al. Prophylactic abdominal drainage after elective colonic resection and suprapromontory anastomosis:A multicenter study controlled by randomization. Arch Surg 1998;133:309-14.
PubMed
5) Urbach DR, et al. Colon and rectal anastomoses do not require routine drainage:A systematic review and meta-analysis. Ann Surg 1999;229:174-80.
 
6) Jesus EC, et al. Prophylactic anastomotic drainage for colorectal surgery. Cochrane Database Syst Rev 2004;4:CD002100.
PubMed
7) Sugar PM, et al. Randomized trial of pelvic drainage after rectal resection. Dis Colon Rectum 1995;38:254-8.
 
8) Cavaliere D, et al. Is a drain necessary after anterior resection of the rectum? A systematic review and meta-analysis. Int J Colorectal Dis 2019;34:973-81.
PubMed
9) Franco D, et al. Hepatectomy without abdominal drainage. Results of a prospective study in 61 patients. Ann Surg 1989;210:748-50.
PubMed
10) Van Buren G, et al. A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitonial drainage. Ann Surg 2014;259:605-12.
 
11) Wang YC, et al. Prophylactic intra-peritoneal drain placement following pancreaticoduodenectomy:A systematic review and meta-analysis. World J Gasroenterol 2015;21:2510-21.
PubMed
12) Haaga JR, et al. CT detection and aspiration of abdominal abscesses. AJR Am J Roentgenol 1977;128:465-74.
PubMed
13) Gerzof SG, et al. Percutaneous catheter drainage of abdominal abscesses guided by ultrasound and computed tomography. AJR Am J Roentgenol 1979;133:1-8.
PubMed
14) Phitayakorn R, et al. Standardized algorithms for management of anastomotic leaks and related abdominal and pelvic abscesses after colorectal surgery. World J Surg 2008;32:1147-56.
PubMed
15) Bernini A, et al. Computed tomography-guided percutaneous abscess drainage in intestinal disease:Factors associated with outcome. Dis Colon Rectum 1997;40:1009-13.
PubMed
P.135 掲載の参考文献
1) Qu YA, Moreillon P. Staphylococcus aureus (Including Staphylococcal Toxic Shock Syndrome). In:Bennett JE, et al, ed. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Philadelphia:Elsevier;2019. p.2393-431.
 
2) Rupp ME, Fey PD. Staphylococcus epidermidis and Other Coagulase-Negative Staphylococci. In:Bennett JE, et al, ed. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Philadelphia:Elsevier;2019. p.2432-43.
 
3) 梅田昭子. ブドウ球菌とその関連球菌. 吉田眞一, ほか編. 戸田新細菌学. 改訂34版. 東京:南山堂;2013. p.236-44.
 
4) Siegel JD, et al. 2007 Guideline for Isolation Precautions:Preventing Transmission of Infectious Agents in Healthcare Settings. Am J Infect Control 2007;35:S65-164.
 
5) MRSA感染症の治療ガイドライン作成委員会, 編. MRSA感染症の治療ガイドライン2019年改訂版. 東京:公益社団法人 日本化学療法学会, 一般社団法人 日本感染症学会;2019.
 
6) Siegel JD, et al. Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006. Am J Infect Control 2007;35(10 Suppl 2):S165-93.
 
7) 笠原 敬. グリコペプチド系抗菌薬. 公益社団法人 日本化学療法学会, 抗菌化学療法認定医認定制度審議委員会, 編. 抗菌薬適正使用生涯教育テキスト. 第3版. 東京:公益社団法人 日本化学療法学会;2020. p.190-200.
 
8) 日本化学療法学会/日本TDM学会 抗菌薬TDMガイドライン作成委員会/TDMガイドライン策定委員会抗菌薬小委員会, 編. 抗菌薬TDM臨床実践ガイドライン2022.
 
9) 高橋 聡. アミノグリコシド系抗菌薬. 公益社団法人 日本化学療法学会, 抗菌化学療法認定医認定制度審議委員会, 編. 抗菌薬適正使用生涯教育テキスト. 第3版. 東京:公益社団法人 日本化学療法学会;2020. p.137-46.
 
10) 加藤英明. 環状リポペプチド系抗菌薬. 公益社団法人 日本化学療法学会, 抗菌化学療法認定医認定制度審議委員会, 編. 抗菌薬適正使用生涯教育テキスト. 第3版. 東京:公益社団法人 日本化学療法学会;2020. p.212-7.
 
11) 小泉祐介. オキサゾリジノン系抗菌薬. 公益社団法人 日本化学療法学会, 抗菌化学療法認定医認定制度審議委員会, 編. 抗菌薬適正使用生涯教育テキスト. 第3版. 東京:公益社団法人 日本化学療法学会;2020. p.201-11
 
P.143 掲載の参考文献
1) Bennett JE, et al, ed. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Expert consult. Philadelphia:Elsevier;2020.
 
2) Antimicrobial resistance in the EU/EEA(EARS-Net)-Annual Epidemiological Report for 2019. https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019[2022年8月17日閲覧]
 
3) 厚生労働省院内感染対策サーベイランス事業. 院内感染対策サーベイランス部門. https://janis.mhlw.go.jp/report/kensa.html[2022年8月17日閲覧]
 
4) 2020年におけるバンコマイシン耐性腸球菌感染症届出患者の増加について. IASR Vol.42, p.100-101:2021年5月号. https://www.niid.go.jp/niid/ja/vre-m/vre-iasrs/10264-495p01.htmls
 
5) Weiner-Lastinger LM, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections:Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol 2020;41:1-18.
 
6) Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 2004;23:73-7.
PubMed
7) Pien BC, et al. The clinical and prognostic importance of positive blood cultures in adults. Am J Med 2010;123:819-28.
PubMed
8) Bouza E, et al. The NOVA score:A proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis 2015;60:528-35.
 
9) Berge A, et al. The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary. Infection 2019;47:45-50.
 
10) Dahl A, et al. Risk Factors of Endocarditis in Patients With Enterococcus faecalis Bacteremia:External Validation of the NOVA Score. Clin Infect Dis 2016;63:771-5.
PubMed
11) Rosselli Del Turco E, et al. How do I manage a patient with enterococcal bacteraemia ? Clin Microbiol Infect 2021;27:364-71.
 
12) Beganovic M, et al. A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clin Infect Dis 2018;67:303-9.
PubMed
13) Lee RA, et al. Infectious Diseases Consultation Is Associated With Decreased Mortality in Enterococcal Bloodstream Infections. Open Forum Infect Dis 2020;7:ofaa064.
PubMed
14) Chuang YC, et al. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia. Clin Infect Dis 2017;64:1026-34.
PubMed
15) Britt NS, et al. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clin Infect Dis 2017;64:605-13.
PubMed
16) Falagas ME, et al. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections:Meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66.
PubMed
P.151 掲載の参考文献
1) Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens:Epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998;11:589-603.
PubMed
2) Yu VL, et al. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis 2007;13:986-93.
PubMed
3) Czaja CA, et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007;45:273-80.
PubMed
4) Gomi H, et al. Tokyo Guidelines 2018:Antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci 2018;25:3-16.
PubMed
5) Fuxench-Lopez Z, Ramirez-Ronda CH. Pharyngeal flora in ambulatory alcoholic patients:Prevalence of gram-negative bacilli. Arch Intern Med 1978;138:1815-6.
PubMed
6) Gupta NM, et al. Association Between Alcohol Use Disorders and Outcomes of Patients Hospitalized With Community-Acquired Pneumonia. JAMA Netw Open 2019;2:e195172.
PubMed
7) Siu LK et al. Klebsiella pneumoniae liver abscess:A new invasive syndrome. Lancet Infect Dis 2012;12:881-7.
PubMed
8) Lee HC, et al. Clinical implications of hypermucoviscosity phenotype in Klebsiella pneumoniae isolates:Association with invasive syndrome in patients with community-acquired bacteraemia. J Intern Med 2006;259:606-14.
PubMed
9) Asensio A, et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit:Antibiotic use as risk factor for colonization and infection. Clin Infect Dis 2000;30:55-60.
 
10) Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
PubMed
11) 荒川宣親. β-ラクタマーゼの機能分類と分子分類. 日本細菌学雑誌 1999;54:639-49.
 
12) カルバペネム耐性腸内細菌科細菌感染症. IASR Vol. 40, No.2(No. 468)February 2019. https://www.niid.go.jp/niid/ja/iasr-vol40/8612-idx468.html
 
13) 感染症法に基づくカルバペネム耐性腸内細菌科細菌感染症の届出状況2019年. 国立感染症研究所 感染症疫学センター. 2020年12月(掲載日:2021年4月25日). https://www.niid.go.jp/niid/ja/cre-m/cre-idwrs/10319-cre-210423.html
 
14) 厚生労働省院内感染対策サーベイランス事業 検査部門. JANIS. https://janis.mhlw.go.jp/section/index.html#kensa
 
15) Fukuchi T, et al. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. BMC Infect Dis 2016;16:427.
PubMed
16) 下野信行, 西田留梨子. カルバペネム耐性腸内細菌科細菌(CRE)感染症の治療. 日本化学療法学会雑誌2016;64:742-9.
 
P.158 掲載の参考文献
1) Kapoor R. Acinetobacter infection. N Engl J Med 2008;358:2845-6.
PubMed
2) Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358:1271-81.
PubMed
3) Peleg AY, et al. Acinetobacter baumannii:Emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-82.
PubMed
4) Dijkshoorn L, et al. An increasing threat in hospitals:Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007;5:939-51.
PubMed
5) Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8:751-62.
PubMed
6) Falagas ME, et al. Community-acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis 2007;26:857-68.
PubMed
7) 小清水直樹, ほか. 急激な経過をたどったAcinetobacter baumanniiによる市中肺炎の1剖検例. 感染症誌 2009;83:392-7.
 
8) Ozaki T, et al. Community-acquired Acinetobacter baumannii meningitis in a previously healthy 14-month-old boy. J Infect Chemother 2009;15:322-4.
 
9) Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria:An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
PubMed
10) 田辺正樹, ほか. 海外帰国患者より多剤耐性アシネトバクターおよび多剤耐性緑膿菌が同時に検出された事例に関する報告. IASR Vol. 35 p.244-6:2014年10月号.
 
11) 地方独立行政法人静岡市立静岡病院. 多剤耐性アシネトバクター検出事例に関するご報告. 2018年8月. https://www.shizuokahospital.jp/media/Acinetobacter1.pdf
 
12) Leclerq R, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2013;19:141-60.
 
13) Moffatt JH, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;54:4971-7.
PubMed
14) Adams MD, et al. Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System. Antimicrob Agents Chemother 2009;53:3628-34.
PubMed
15) Coyne S, et al. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 2011;55:947-53.
PubMed
16) He X, et al. Biofilm formation caused by clinical Acinetobacter baumannii isolates is associated with overexpression of the AdeFGH efflux pump. Antimicrob Agents Chemother 2015;59:4817-25.
PubMed
17) Hidron AI, et al. NHSN annual update:Antimicrobial-resistant pathogens associated with healthcare-associated infections:Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
 
18) Wang YF, Dowzicky MJ. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn Microbiol Infect Dis 2010;68:73-9.
PubMed
19) Shlaes DM, et al. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 2013;57:4605-7.
PubMed
20) Mendes RE, et al. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations:Report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009;63:55-9.
 
21) 原田壮平. 多剤耐性菌-最新の疫学から治療のコンセプトまで. Hospitalist 2017;5:457-68.
 
22) Hayashi M, et al. Reduction in chlorhexidine efficacy against multi-drug-resistant Acinetobacter baumannii international clone II. J Hosp Infect 2017;95:318-23.
 
23) Zarrilli R, et al. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 2013:41:11-9.
PubMed
24) 厚生労働省院内感染対策サーベイランス事業:公開情報. https://janis.mhlw.go.jp/report/index.html[2022年8月16日閲覧]
 
25) Levin AS. Multiresistant Acinetobacter infections:A role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002;8:144-53.
PubMed
26) Doi Y, et al. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009;15:980-2.
PubMed
27) Kim YK, et al. Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. J Thorac Dis 2017;9:555-67.
PubMed
28) Lu Q, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistan Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012;117:1335-47.
 
P.169 掲載の参考文献
1) Williams EP, Cameron K. Infection by the Bacillus pyocyaneus a Cause of Infantile Mortality. Public Health Pap Rep 1894;20:355-60.
PubMed
2) Wieland K, et al. Nosocomial outbreaks caused by Acinetobacter baumannii and Pseudomonas aeruginosa:Results of a systematic review. Am J Infect Control 2018;46:643-8.
PubMed
3) Senda K, et al. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996;40:349-53.
 
4) Yokoyama K, et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 2003;362(9399):1888-93.
PubMed
5) Wachino J, et al. Aminoglycoside Resistance:Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases. Infect Dis Clin North Am 2020;34:887-902.
PubMed
6) Recio R, et al. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone:Facing the perfect storm. Int J Antimicrob Agents 2018;52:172-9.
PubMed
7) Del Barrio-Tofino E, et al. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases:2020 update. Int J Antimicrob Agents 2020;56:106196.
 
8) 厚生労働省. 薬剤耐性緑膿菌感染症. https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-42-01.html
 
9) Yoo JS, et al. Dissemination of genetically related IMP-6-producing multidrug-resistant Pseudomonas aeruginosa ST235 in South Korea. Int J Antimicrob Agents 2012;39:300-4.
PubMed
10) Shindo Y, et al. Risk Factors for Drug-Resistant Pathogens in Community-acquired and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2013;188:985-95.
PubMed
11) Weiner-Lastinger LM, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections:Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol 2020;41:1-18.
 
12) Mermel LA, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45.
 
13) Kalil AC, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia:2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61-111.
 
14) Bennett JE, et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier;2019
 
15) Thaden JT, et al. Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria. Antimicrob Agents Chemother 2017;61:e02671-16.
PubMed
16) Metlay JP, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200:e45-67.
 
17) Mano Y, et al. Molecular analysis of the integrons of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan. BMC Microbiol 2015;15:41.
PubMed
18) Lyon MD, et al. In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1986;30:25-30.
PubMed
19) Paul M, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients:Systematic review and meta-analysis of randomised trials. BMJ 2004;328(7441):668.
PubMed
20) Sorin M, et al. Nosocomial transmission of imipenem-resistant Pseudomonas aeruginosa following bronchoscopy associated with improper connection to the Steris System 1 processor. Infect Control Hosp Epidemiol 2001;22:409-13.
 
21) Seki M, et al. Nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa caused by damaged transesophageal echocardiogram probe used in cardiovascular surgical operations. J Infect Chemother 2013;19:677-81.
 
22) Weberm DJ, Talbot TR. Mayhall's Hospital Epidemiology and Infection Prevention. 5th ed. Philadelphia, PA:Wolters Kluwer;2001.
 
23) Matos ECO, et al. Mortality in patients with multidrug-resistant Pseudomonas aeruginosa infections:A meta-analysis. Rev Soc Bras Med Trop 2018;51:415-20.
PubMed
P.176 掲載の参考文献
1) Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009;22:161-82.
PubMed
2) Donnenberg MS. Enterobacteriaceae. In:Bennett JE, et al, ed. Mandell, Douglas, & Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA:Elsevier;2015. p.2503-17.
 
3) Mizrahi A, et al. Infections caused by naturally AmpC-producing Enterobacteriaceae:Can we use third-generation cephalosporins? A narrative review. Int J Antimicrob Agents 2020;55:105834.
PubMed
4) レカルブリオ(R) インタビューフォーム. 2021年8月改訂第2版.
 
P.185 掲載の参考文献
1) Sannes MR, et al. Virulence factor profiles and phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control subjects. J Infect Dis 2004;190:2121-28.
PubMed
2) Lefort A, et al. Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia. J Clin Microbiol 2011;49:777-83.
PubMed
3) カルバペネム耐性腸内細菌科細菌(carbapenem-resistant Enterobacteriaceae:CRE) 病原体サーベイランス, 2019年. IASR Vol. 42 p123-4:2021年6月号. https://www.niid.go.jp/niid/ja/cre-m/cre-iasrd/10462-496d01.html[. Accessed Aug 19, 2022]
 
4) Abe T, et al. Epidemiology of sepsis and septic shock in intensive care units between sepsis-2 and sepsis-3 populations:Sepsis prognostication in intensive care unit and emergency room(SPICE-ICU). J Intensive Care 2020;8:44.
PubMed
5) Samet A, et al. Leukemia and risk of recurrent Escherichia coli bacteremia:Genotyping implicates E. coli translocation from the colon to the bloodstream. Eur J Clin Microbiol Infect Dis 2013;32:1393-400.
 
6) Harris PNA, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance:A Randomized Clinical Trial. JAMA 2018;320:984-94.
PubMed
7) Bassetti M, et al. Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections:A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infect Dis 2020;7:ofaa139.
PubMed
8) Shinjoh M, et al. Recent trends in pediatric bacterial meningitis in Japan, 2016-2018-S. agalactiae has been the most common pathogen. J Infect Chemother 2020;26:1033-41.
PubMed
9) Brouwer MC, et al. Clinical characteristics and outcome of brain abscess:Systematic review and meta-analysis. Neurology 2014;82:806-13.
PubMed
10) Doi A, et al. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis 2013;17:e159-63.
PubMed
P.194 掲載の参考文献
1) World Health Organization. Treatment of drug-susceptible tuberculosis:Rapid communication. Geneva:World Health Organization;2021. Licence:CC BY-NC-SA 3.0 IGO.
 
2) Chiba Y. Significance of endogenous reactivation 30 year follow-up of tuberculin positive converters. Bull IUAT 1974;49:321-4.
 
3) World Health Organization. Global tuberculosis report 2021. Geneva:World Health Organization;2021. Licence:CC BY-NC-SA 3.0 IGO.
 
4) 公益財団法人結核予防会, 編. 結核の統計2022. 東京:公益財団法人結核予防会;2022.
 
5) 日本結核病学会予防委員会・治療委員会. 潜在性結核感染症治療指針. 結核 2013;88:497-512.
Medical*Online
6) Roy A, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children:Systematic review and meta-analysis. BMJ 2014;349:g4643.
PubMed
7) Abubakar I, et al. Assessing the effect of foreign travel and protection by BCG vaccination on the spread of tuberculosis in a low incidence country, United Kingdom, October 2008 to December 2009. Euro Surveill 2011;16:19826.
 
8) Trunz BB, et al. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide:A meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:1173-80.
PubMed
9) Takayanagi K, et al. Analysis of interferon-gamma release assay for monitoring of the efficacy of anti-tuberculosis chemotherapy. Jpn J Infect Dis 2011;64:133-8.
PubMed
10) 厚生労働省健康局結核感染症課長. 結核医療の基準の一部改正について. 健感発0418 第1号 平成30年4月18日.
 
P.201 掲載の参考文献
1) Ngwa DN, et al. Treatment of pneumococcal infection by using engineered human C-reactive protein in a mouse model. Front Immunol 2020;11:586669.
 
2) Haroon A, et al. Pulmonary computed tomography findings in 39 cases of Streptococcus pneumoniae pneumonia. Intern Med 2012;51:3343-9.
PubMed
3) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会, 編. 成人肺炎診療ガイドライン2017. 東京:日本呼吸器学会;2017.
 
4) McGee S, Hirschmann J. Use of corticosteroids in treating infectious diseases. Arch Intern Med 2008;168:1034-46.
PubMed
5) Bogaert D, et al. Streptococcus pneumoniae colonisation:The key to pneumococcal disease. Lancet Infect Dis 2004;4:144-54.
PubMed
6) Nishimoto AT, et al. Pneumolysin:Pathogenesis and therapeutic target. Front Microbiol 2020;11:1543.
PubMed
P.209 掲載の参考文献
1) Stevens DL, Bryant AE. Necrotizing Soft-Tissue Infections. N Engl J Med 2017;377:2253-65.
PubMed
2) Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections:2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:e10-52.
 
3) Walker MJ, et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin Microbiol Rev 2014;27:264-301.
PubMed
4) 竹本訓彦, ほか. 次世代シーケンス(NGS)による劇症型レンサ球菌の病原性解析. 日本化学療法学会雑誌 2017;65:745-50.
 
5) Bruun T, et al. Risk Factors and Predictors of Mortality in Streptococcal Necrotizing Soft-tissue Infections:A Multicenter Prospective Study. Clin Infect Dis 2021;72:293-300.
PubMed
6) 溶血性レンサ球菌感染症2012年～2015年6月. IASR 2015;36:147-9.
 
7) Bechar J, et al. Laboratory risk indicator for necrotising fasciitis(LRINEC) score for the assessment of early necrotising fasciitis:A systematic review of the literature. Ann R Coll Surg Engl 2017;99:341-6.
PubMed
8) Parks T, et al. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome:A Systematic Review and Meta-analysis. Clin Infect Dis 2018;67:1434-6.
PubMed
9) 田之上桂子, ほか. 劇症型溶連菌感染症に対しPMX-DHPとCHDFを併用し救命しえた1例. 防衛医大誌 2020;44:146-51.
 
10) Siegel JD, et al. 2007 Guideline for Isolation Precautions:Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007;35(10 Suppl 2):S65-164.
 
P.218 掲載の参考文献
1) Kuroki T, et al. Outbreak of Legionnaire's Disease Caused by Legionella pneumophila Serogroups 1 and 13. Emerg Infect Dis 2017;23:349-51.
PubMed
2) Nakanishi M, et al. Clinical and computed tomographic features of Legionella pneumonia with negative urine antigen test results. Respr Investig 2021;59:204-11.
 
3) FDA Drug Safety Communication:Drug labels for the Tumor Necrosis Factor-alpha (TNF& alpha;)blockers now include warnings about infection with Legionella and Listeria bacteria. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drugsafety-communication-drug-labels-tumor-necrosis-factor-alpha-tnfa-blockers-now-include
 
4) Bolliger R, et al. Validation of a prediction rule for Legionella pneumonia in emergency department patients. Open Forum Infect Dis 2019;6:ofz 268.
 
5) Allgaier J, et al. Risk factors, Management, and Outcomes of Legionella pneumonia in a large, nationally representative sample. Chest 2021;159:1782-92.
 
6) Ito A, et al. Evaluation of a novel urinary antigen test kit for diagnosing Legionella pneumonia. Int J Infect Dis 2021;103:42-7.
PubMed
7) Guy SD, et al. Legionella pneumophila lung abscess associated with immune suppression. Intern Med J 2011;41:715-21.
PubMed
8) Miyara T, et al. Rapidly expanding lung abscess caused by Legionella pneumophila in immunocompromised patients:A report of two cases. Intern Med 2002;41:133-7.
PubMed
9) Kato H, et al. Meta-analysis of fluoroquinolones versus macrolides for treatment of legionella pneumonia. J Infect Chemother 2021;27:424-33.
PubMed
10) Arakaki N, et al. Concurrent infection with Legionella pneumophila and Pneumocystis carinii in a patient with adult T cell leukemia. Internal Med 1999;38:160-3.
 
11) Tateda K, et al. Hyperoxia mediates acute lung injury and increased lethality in murine Legionella pneumonia:The role of apoptosis. J Immunol 2003;170:4209-16.
PubMed
12) Naqvi A, et al. Outcomes of severe Legionella pneumonia requiring extracorporeal membrane oxygenation(ECMO). J Crit Care 2021;61:103-6.
PubMed
P.227 掲載の参考文献
1) 小田 紘. 偏性嫌気性菌. クロストリジウム属. 吉田眞一, ほか編. 戸田新細菌学. 改訂34版. 東京:南山堂;2013. p.385-99.
 
2) Ganesh Kumar AV, et al. Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus:A randomized, controlled trial. Ann Trop Med Parasitol 2004;98:59-63.
PubMed
3) 一般社団法人 日本環境感染学会 ワクチンに関するガイドライン改訂委員会. 医療関係者のためのワクチンガイドライン 第2版追補版 髄膜炎菌ワクチン・破傷風トキソイド. 環境感染誌2017;32 Suppl I:S4.
 
4) グラクソ・スミスクライン株式会社. A型ボツリヌス毒素製剤ボトックス注用50単位, ボトックス注用100単位. 添付文書.
 
5) 山口育男. Clostridium perfringens. 堀井俊伸, 監修, 犬塚和久, 編. 微生物検査ナビ. 第2版. 東京:栄研化学株式会社;2016. p.310-1.
 
6) 井谷智尚. ウェルシュ菌腸炎. 大川清孝, 清水誠治, 編. 感染性腸炎A to Z. 第2版. 東京:医学書院;2013. p.69-70.
 
7) 嫌気性菌感染症診断・治療ガイドライン作成委員会. ウェルシュ菌による食中毒. 日本化学療法学会, 日本嫌気性菌感染症研究会, 編. 嫌気性菌感染症診断・治療ガイドライン2007. 東京:協和企画;2007. p.183-5.
 
8) 嫌気性菌感染症診断・治療ガイドライン作成委員会. 皮膚軟部組織感染症. 日本化学療法学会, 日本嫌気性菌感染症研究会, 編. 嫌気性菌感染症診断・治療ガイドライン2007. 協和企画;2007. p.95-100.
 
9) Clostridioides(Clostridium)difficile 感染症診療ガイドライン作成委員会. CDIの定義. 日本化学療法学会・日本感染症学会CDI診療ガイドライン作成委員会, 編. Clostridioides(Clostridium)difficile感染症診療ガイドライン. 杏林舎;2018. p.22-24.
 
10) van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-5.
PubMed
P.235 掲載の参考文献
1) 日本感染症学会. 感染症トピックス. 新型コロナウイルス感染症. 最終更新日2022年10月20日. https://www.kansensho.or.jp/modules/topics/index.php?content_id=31[accessed on November 18, 2022]
 
2) Wang D, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
PubMed
3) 関 雅文. SARS. 永井良三, 編. 今日の診断指針. 第8版. 東京:医学書院;2020.
 
4) 今井 悠, ほか. 当院での軽症COVID-19の症例報告. 日本感染症学会. 2020年4月20日公開. https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_200421_1.pdf[accessed on August 30, 2022]
 
5) 厚生労働省. 成人の新型インフルエンザ治療ガイドライン. 第二版. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/infulenza/kenkyu.html
 
6) Seki M, et al. Severe respiratory failure due to co-infection with human metapneumovirus and Streptococcus pneumoniae. Respiratory Medicine Case Reports 2014;12:13-5.
PubMed
7) Kurai D, et al. Pathogen profiles and molecular epidemiology of respiratory viruses in Japanese inpatients with community-acquired pneumonia. Respir Investig 2016;54:255-63.
PubMed
8) 関 雅文. 麻疹肺炎. 領域別症候群シリーズ. 感染症症候群II. 東京:日本臨牀社;1999, p.99.
 
9) 関 雅文. 水痘肺炎. 新領域別症候群シリーズ. 呼吸器症候群(第2版)I-その他の呼吸器疾患を含めて. 東京:日本臨牀社;2008, p.136.
 
10) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会, 編. 成人肺炎診療ガイドライン 2017. 東京:日本呼吸器学会.
 
11) 関 雅文. インフルエンザでひき起こされる肺炎球菌感染症の高感受性と重症化. 呼吸器内科 2014;26:16-21.
 
12) Seki M, et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 2004;24:143-9.
PubMed
13) Bhimraj A, et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Published by IDSA on 4/11/2020. Last updated, 9/24/2021. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
 
14) 関 雅文. 米国感染症学会からの新型コロナウイルス感染症(COVID-19)診療ガイドラインにおける推奨治療薬に関する紹介. 2022年4月4日. https://www.jrs.or.jp/covid19/jrs/20220404201243.html
 
15) 米国CDC webサイト. Your Health. 2022/8/11. https://www.cdc.gov/coronavirus/2019-ncov/your-health/index.html. 2020/8/11.
 
P.244 掲載の参考文献
1) 深在性真菌症のガイドライン作成委員会, 編. 深在性真菌症の診断・治療ガイドライン2014. 東京:協和企画;2014.
 
2) Ueda T, et al. The incidence of endophthalmitis or macular involvement and the necessity of a routine ophthalmic examination in patients with candidemia. PLoS One 2019;14:e0216956.
 
3) 日本医真菌学会 アスペルギルス症の診断・治療ガイドライン作成委員会, 編. アスペルギルス症の診断・治療ガイドライン. 東京:日本医真菌学会;2015.
 
4) 日本医真菌学会 侵襲性カンジダ症の診断・治療ガイドライン作成委員会, 編. 侵襲性カンジダ症の診断・治療ガイドライン. 東京:日本医真菌学会;2013.
 
5) Pappas PG, et al. Clinical Practice Guideline for the Management of Candidiasis:2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50.
 
6) Pfeiffer CD, et al. Diagnosis of invasive aspergillosis using a galactomannan assay:A meta-analysis. Clin Infect Dis 2006;42:1417-27.
PubMed
7) Nam Su Ku, et al. Diagnostic value of the serum galactomannan assay for invasive aspergillosis:It is less useful in non-haematological patients. Scand J Infect Dis 2012;44:600-4.
PubMed
8) Sehgal IS, et al. Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis. J Clin Microbiol 2019;57:e01821-18.
PubMed
9) Kohno S, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis:A multicenter trial in Japan. J Infect 2010;61:410-8.
PubMed
10) Cornely OA, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014;20:5-26.
PubMed
P.252 掲載の参考文献
1) 吉田幸雄, 有薗直樹. 図説人体寄生虫学, 改訂9版. 東京:南山堂;2016.
 
2) 佐藤(大久保)梢, ほか. ダニ媒介性感染症-国内に常在する感染症を主に. 衛生動物 2019;70:3-14.
 
3) 馬原文彦. マダニ媒介性感染症の初期対応-マダニを付けてきたら. 日本医事新報 2018;4909:47-53.
Medical*Online
4) 橋本知幸, 武藤敦彦. マダニ忌避剤の室内試験における効力評価. 殺虫剤研究班のしおり 2014;85:9-16.
 
5) Yu XJ, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011;364:1523-32.
 
6) 馬原文彦, ほか. 日本紅斑熱の臨床所見に関する発生地域別多施設調査. 感染症誌 2015;89:490-2.
 
7) 天野憲一. Weil-Felix 反応におけるリケッチアLPSと プロテウスLPSの共通抗原性. 日細菌誌1998;53:599-610.
 
8) Tai K, et al. Minocycline modulates cytokine and chemokine production in lipopolysaccharide-stimulated THP-1 monocytic cells by inhibiting IκB kinase α/β phosphorylation. Transl Res 2013;161:99-109.
 
9) Hofmann H, et al. Cutaneous Lyme borreliosis:Guideline of the German Dermatology Society. Ger Med Sci 2017;15:Doc 14.
 
10) Kutsuna S, et al. The first case of imported relapsing fever in Japan. Am J Trop Med Hyg 2013;89:460-1.
PubMed
11) Yamano K, et al. Case Report:Clinical Features of a Case of Suspected Borrelia miyamotoi Disease in Hokkaido, Japan. Am J Trop Med Hyg 2017;97:84-7.
PubMed
12) Platonov AE, et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis 2011;17:1816-23.
PubMed
13) Molly PJ, et al. Borrelia miyamotoi Disease in the Northeastern United States:A Case Series. Ann Intern Med 2015;163:91-8.
 
14) 厚生労働省. マダニ媒介性の回帰熱に関するQ&A. 平成25年. https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou18/kaikinetsu_qa.html
 
15) Kato H, et al. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan, 2013-2014. PLoS One 2016;11:e0165207.
PubMed
16) 西條政幸, ほか. ペットからSFTSウイルスに感染し, SFTSを発症した事例報告. IASR 2019;40:117-8.
 
17) 国立感染症研究所. 感染症動向調査で届出られたSFTS症例の概要(2022年7月31日現在)https://www.niid.go.jp/niid/ja/sfts/3143-sfts.html(accessed November 29, 2022)
 
18) Morikawa S, et al. Correlation between SFTS virus antibody positive rate in wild deer and number of SFTS patients(PO842). 17th International Congress in Virology, IUMS, Singapore, July 2017.
 
19) Wang LY, et al. Severe fever with thrombocytopenia syndrome in children:A case report. BMC Infect Dis 2014;14:366.
PubMed
20) Suzuki T, et al. Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections. J Clin Invest 2020;130:799-812.
PubMed
21) Kaneyuki S, et al. Ulcerative lesions with hemorrhage in a patient with severe fever with thrombocytopenia syndrome observed via upper gastrointestinal endoscopy. Jpn J Infect Dis 2016;69:525-7.
 
22) Takahashi T, et al. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis 2014;209:816-27.
PubMed
23) Yoshikawa T, et al. Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load. J Clin Microbiol 2014;52:3325-33.
PubMed
24) Tani H, et al. Efficacy of T-705(Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. mSphere 2016;1:e00061-15.
PubMed
25) 加藤康幸(研究代表者). 平成30年度厚生労働行政推進調査事業費補助金 新興・再興感染症及び予防接種政策推進研究事業 一類感染症等の患者発生時に備えた臨床的対応に関する研究. 重症熱性血小板減少症候群(SFTS)診療の手引き. 改訂新版. 2019.
 
26) Holzmann H, et al. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J Med Viol 1996;48:102-7.
 
27) Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am 2008;22:561-75.
PubMed
28) Heinz FX, et al. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007;25:7559-67.
PubMed
29) 児玉文宏. 札幌におけるダニ媒介脳炎ワクチンの有効性と安全性. バムサジャーナル 2021;33:9-13.
Medical*Online

4章 ベーシック : 敗血症性臓器障害の管理

P.262 掲載の参考文献
1) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020. 日集中医誌 2021;28:S1-411.
 
2) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020. 日救急医会誌 2021;32:S1-411.
 
3) Minds診療ガイドライン作成マニュアル編集委員会. Minds診療ガイドライン作成マニュアル2020 ver.3. 0. 東京:公益財団法人日本医療機能評価機構EBM医療情報部;2021.
 
P.272 掲載の参考文献
1) Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:801-10.
PubMed
2) Vincent J-L, et al. The SOFA(Sepsis-related Organ Failure Assessment)score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-10.
PubMed
3) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020. 日集中医誌 2021;28:S1-411.
 
4) Levy MM, et al. The Surviving Sepsis Campaign Bundle:2018 Update. Crit Care Med 2018;46:997-1000.
PubMed
5) Kraut JA, Madias NE. Lactic Acidosis. N Engl J Med 2014;371:2309-19.
PubMed
6) Sadaka F, et al. Fluid resuscitation in septic shock:The effect of increasing fluid balance on mortality. J Intensive Care Med 2014;29:213-7.
PubMed
7) Monnet X, et al. Prediction of fluid responsiveness:An update. Ann Intensive Care 2016;6:111.
PubMed
8) Vignon P, et al. Comparison of Echocardiographic Indices Used to Predict Fluid Responsiveness in Ventilated Patients. Am J Respir Crit Care Med 2017;195:1022-32.
PubMed
9) Theerawit P, et al. Inferior vena cava diameter variation compared with pulse pressure variation as predictors of fluid responsiveness in patients with sepsis. J Crit Care 2016;36:246-51.
PubMed
10) Marik PE, et al. Hemodynamic parameters to guide fluid therapy. Ann Intensive Care 2011;1:1.
PubMed
11) Wardi G, et al. Equipoise in Appropriate Initial Volume Resuscitation for Patients in Septic Shock With Heart Failure:Results of a Multicenter Clinician Survey. J Intensive Care Med 2020;35:1338-45.
PubMed
12) Douglas IS, et al. Fluid Response Evaluation in Sepsis Hypotension and Shock:A Randomized Clinical Trial. Chest 2020;158:1431-45.
 
13) Rich JD, et al. Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur Respir J 2013;42:125-33.
PubMed
14) Rivers E, et al. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. N Engl J Med 2001;345:1368-77.
PubMed
P.283 掲載の参考文献
1) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020 特別委員会. 日本版敗血症診療ガイドライン2020. 日集中医誌 2021;28:S1-S411.
 
2) Devlin JW, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018;46:e825-73.
PubMed
3) John W. Devlin, et al. 集中治療室における成人患者の痛み, 不穏/鎮静, せん妄, 不動, 睡眠障害の予防および管理のための臨床ガイドライン. Critical Care Medicine. Copyright (C) 2018 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. https://www.sccm.org/getattachment/Clinical-Resources/Guidelines/Guidelines/Guidelines-for-the-Prevention-and-Management-of-Pa/PADIS-Guidelines-Japanese-2019.pdf?lang=en-US[2022年11月25日アクセス]
 
4) 日本集中治療医学会J-PADガイドライン作成委員会. 日本版・集中治療室における成人重症患者に対する痛み・不穏・せん妄管理のための臨床ガイドライン. 日集中医誌2014;21:539-79. https://www.jsicm.org/pdf/2015-J-PAD-guideline.pdf
 
5) 鶴田良介. 敗血症における鎮痛・鎮静. 救急・集中治療 2018;30:742-8.
Medical*Online
6) 鶴田良介. ICU 関連せん妄. 救急・集中治療 2019;31:1338-40.
Medical*Online
7) 鶴田良介. 鎮痛・鎮静. 日本集中治療医学会教育委員会, 編. 日本集中治療医学会専門医テキスト. 第3版. 東京:真興交易医書出版部;2019. p.420-8.
 
8) 鶴田良介. 重症患者の睡眠を考える-睡眠障害はせん妄をもたらすのか? ICUとCCU 2018;42:457-463.
Medical*Online
9) 鶴田良介, ほか. 重症患者の睡眠障害. 日集中医誌 2017;24:389-97.
 
P.297 掲載の参考文献
1) Ashbaugh DG, et al. Acute respiratory distress in adults. Lancet 1967;2:319-23.
PubMed
2) Petty TL, Ashbaugh DG. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. Chest 1971;60:233-9.
PubMed
3) Murray JF, et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.
PubMed
4) Bernard GR, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24.
PubMed
5) ARDS Definition Task Force;Ranieri VM, et al. Acute respiratory distress syndrome:the Berlin Definition. JAMA 2012;307:2526-33.
PubMed
6) Tomashefski JF Jr. Pulmonary pathology of the acute respiratory distress syndrome:Diffuse alveolar damage. In:Matthay MA, ed. Acute Respiratory Distress Syndrome. New York:Marcel Dekker;2003. p.75-108.
 
7) Bianchi ME. DAMPs, PAMPs and alarmins:All we need to know about danger. J Leukoc Biol 2007;81:1-5.
 
8) Gorin AB, Stewart PA. Differential permeability of endothelial and epithelial barriers to albumin flux. J Appl Physiol Respir Environ Exerc Physiol 1979;47:1315-24.
 
9) Overgaard CE, et al. Roles for claudins in alveolar epithelial barrier function. Ann N Y Acad Sci 2012;1257:167-74.
PubMed
10) Forster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 2008;130:55-70.
PubMed
11) Matsuda N, et al. Silencing of fas-associated death domain protects mice from septic lung inflammation and apoptosis. Am J Respir Crit Care Med 2009;179:806-15.
PubMed
12) Matsuda N, et al. Silencing of caspase-8 and caspase-3 by RNA interference prevents vascular endothelial cell injury in mice with endotoxic shock. Cardiovasc Res 2007;76:132-40.
PubMed
13) Zhou G, et al. Regulation of alveolar epithelial function by hypoxia. Eur Respir J 2008;31:1107-13.
PubMed
14) Matsuda N. Alert cell strategy in SIRS-induced vasculitis:Sepsis and endothelial cells. J Intensive Care 2016;4:21.
PubMed
15) Thiam HR, et al. Cellular Mechanisms of NETosis. Annu Rev Cell Dev Biol 2020;36:191-218.
PubMed
16) Ferguson ND, et al. The Berlin definition of ARDS:An expanded rationale, justification, and supplementary material. Intensive Care Med 2012;38:1573-82.
PubMed
17) Britos M, et al. The value of positive end-expiratory pressure and FiO2 criteria in the definition of the acute respiratory distress syndrome. Crit Care Med 2011;39:2025-30.
PubMed
18) Evans L, et al. Surviving sepsis campaign:International guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021;47:1181-247.
PubMed
19) Devlin JW, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med 2018;46:e825-73.
PubMed
20) Kalil AC, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia:2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61-111.
 
21) Peter JV, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome(ARDS) in adults:Meta-analysis. BMJ 2008;336:1006-9.
PubMed
22) Meduri GU, et al. Methylprednisolone infusion in early severe ARDS:Results of a randomized controlled trial. Chest 2007;131:954-63.
PubMed
23) Steinberg KP, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-84.
PubMed
24) Meduri GU, et al. Activation and regulation of systemic inflammation in ARDS:Rationale for prolonged glucocorticoid therapy. Chest 2009;136:1631-43.
PubMed
25) Rubenfeld GD, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-93.
PubMed
26) Villar J, et al;ALIEN Network. The ALIEN study:Incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011;37:1932-41.
 
27) Erickson SE, et al. Recent trends in acute lung injury mortality:1996-2005. Crit Care Med 2009;37:1574-9.
PubMed
P.314 掲載の参考文献
1) Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:801-10.
PubMed
2) Seymour CW, et al. Assessment of Clinical Criteria for Sepsis:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:762-74.
PubMed
3) Vincent JL, et al. The SOFA(Sepsis-related Organ Failure Assessment)score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
 
4) Evans L, et al. Surviving sepsis campaign:International guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021;47:1181-247.
PubMed
5) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
PubMed
6) Levy MM, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
PubMed
7) Jin X, et al. New molecular mechanisms for cardiovascular disease:Contribution of endothelium-derived hyperpolarizing factor in the regulation of vasoconstriction in peripheral resistance arteries. J Pharmacol Sci 2011;116:332-6.
PubMed
8) Matsuda N, et al. Increased death receptor pathway of apoptotic signaling in septic mouse aorta:Effect of systemic delivery of FADD siRNA. Am J Physiol Heart Circ Physiol 2010;298:H92-101.
PubMed
9) Matsuda N. Alert cell strategy in SIRS-induced vasculitis:Sepsis and endothelial cells. J Intensive Care 2016;4:21.
PubMed
10) Chen ZJ, et al. Recent progress in alpha1-adrenergic receptor research. Acta Pharmacol Sin 2005;26:1281-7.
PubMed
11) Tykocki NR, et al. Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles. Compr Physiol 2017;7:485-581.
PubMed
12) Russell JA, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87.
PubMed
13) Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007;35:1599-608.
PubMed
14) Hollenberg SM, et al. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol 2021;18:424-34.
PubMed
15) 松田直之, ほか. 心筋細胞におけるGTP結合蛋白質の循環制御機構-循環器病態における最近の知見. 循環制御 2002:23:171-9.
Medical*Online
16) Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415:198-205.
 
17) Eisner DA, et al. Calcium and Excitation-Contraction Coupling in the Heart. Circ Res 2017;121:181-95.
PubMed
18) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン 2020 特別委員会. 日本版敗血症診療ガイドライン2020. 日集中医誌 2021;28:S1-411. https://www.jsicm.org/pdf/jjsicm28Suppl.pdf[2022年11月10日閲覧]
 
P.321 掲載の参考文献
1) Kidney Disease:Improving Global Outcomes(KDIGO)Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1-138. https://kdigo.org/wp-content/uploads/2016/10/2013KDIGO_AKI_ES_Japanese.pdf
 
2) AKI(急性腎障害)診療ガイドライン作成委員会, 編. AKI(急性腎障害)診療ガイドライン2016. 日腎会誌 2017;59:419-533.
 
3) Gaudry S, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med 2016;375:122-33.
PubMed
4) Zarbock A, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury:The ELAIN Randomized Clinical Trial. JAMA 2016;315:2190-9.
PubMed
5) STARRT-AKI Investigators, et al. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med 2020;383:240-51.
PubMed
6) Gaudry S, et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury:A systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet 2020;395:1506-15.
PubMed
7) Dellinger RP, et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level:The EUPHRATES Randomized Clinical Trial. JAMA 2018;320:1455-63.
PubMed
8) Nadim MK, et al. COVID-19-associated acute kidney injury:Consensus report of the 25th Acute Disease Quality Initiative(ADQI)Workgroup. Nat Rev Nephrol 2020;16:747-64.
PubMed
9) Basile DP, et al. Progression after AKI:Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments. J Am Soc Nephrol 2016;27:687-97.
PubMed
P.331 掲載の参考文献
1) 日本血栓止血学会学術標準化委員会DIC部会;丸山征郎, ほか. 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会誌 2009;20:77-113.
 
2) 射場敏明. 好中球が関与する凝固の活性化と血栓形成. 日本血栓止血学会誌 2016;27:308-15.
 
3) Lorente L, et al. The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis. PLoS One 2015;10:e0129565.
PubMed
4) 日本救急医学会DIC委員会. 急性期DIC診断基準-5. Dダイマー/FDP換算表の項の改訂. 日本救急医学会雑誌 2013;24:105-15.
 
5) Taylor FB Jr, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
 
6) Iba, T, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost 2019;17:1989-94.
PubMed
7) Hayakawa M, et al. Characteristics, treatments, and outcomes of severe sepsis of 3195 ICU-treated adult patients throughout Japan during 2011-2013. J Intensive Care 2016;4:44.
PubMed
8) Gando S, et al. Role of disseminated intravascular coagulation in severe sepsis. Thromb Res 2019;178:182-8.
PubMed
9) Matsubara T, et al. Significance of plasma fibrinogen level and antithrombin activity in sepsis:A multicenter cohort study using a cubic spline model. Thromb Res 2019;181:17-23.
PubMed
P.339 掲載の参考文献
1) Rudd KE, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017:Analysis for the global burden of disease study. Lancet 2020;395:200-11.
PubMed
2) Yende S, et al. Long-term quality of life among survivors of severe sepsis:Analyses of two international trials. Crit Care Med 2016;44:1461-7.
PubMed
3) Cuthbertson BH, et al. Quality of life in the five years after intensive care:A cohort study. Crit Care 2010;14:R6.
PubMed
4) Kamdar BB, et al. Return to work after critical illness:A systematic review and meta-analysis. Thorax 2020;75:17-27.
PubMed
5) Needham DM, et al. Improving long-term outcomes after discharge from intensive care unit:Report from a stakeholders' conference. Crit Care Med 2012;40:502-9.
PubMed
6) Kawakami D, et al. Prevalence of post-intensive care syndrome among Japanese intensive care unit patients:A prospective, multicenter, observational J-PICS study. Crit Care 2021;25:69.
PubMed
7) Rousseau AF, et al. Long-term outcomes after critical illness:Recent insights. Crit Care 2021;25:108.
PubMed
8) Nakanishi N, et al. Upper and lower limb muscle atrophy in critically ill patients:An observational ultrasonography study. Intensive Care Med 2018;44:263-4.
PubMed
9) Nakanishi N, et al. Upper limb muscle atrophy associated with in-hospital mortality and physical function impairments in mechanically ventilated critically ill adults:A two-center prospective observational study. J Intensive Care 2020;8:87.
PubMed
10) Stevens RD, et al. Neuromuscular dysfunction acquired in critical illness:A systematic review. Intensive Care Med 2007;33:1876-91.
PubMed
11) Van Aerde N, et al. Five-year impact of ICU-acquired neuromuscular complications:A prospective, observational study. Intensive Care Med 2020;46:1184-93.
PubMed
12) Nikayin S, et al. Anxiety symptoms in survivors of critical illness:A systematic review and meta-analysis. Gen Hosp Psychiatry 2016;43:23-9.
PubMed
13) Rabiee A, et al. Depressive symptoms after critical illness:A systematic review and meta-analysis. Crit Care Med 2016;44:1744-53.
PubMed
14) Parker AM, et al. Posttraumatic stress disorder in critical illness survivors:A metaanalysis. Crit Care Med 2015;43:1121-9.
PubMed
15) Patel MB, et al. Incidence and risk factors for intensive care unit-related post-traumatic stress disorder in veterans and civilians. Am J Respir Crit Care Med 2016;193:1373-81.
PubMed
16) Davydow DS, et al. Symptoms of depression in survivors of severe sepsis:A prospective cohort study of older Americans. Am J Geriatr Psychiatry 2013;21:887-97.
PubMed
17) Puntillo K, et al. Symptoms experienced by intensive care unit patients at high risk of dying. Crit Care Med 2010;38:2155-60.
PubMed
18) Tripathy S, et al. ICU memories and patient outcomes in a low middle-income country:A longitudinal cohort study. Crit Care Med 2021;49:e978-88.
 
19) Honarmand K, et al. Natural history of cognitive impairment in critical illness survivors. A systematic review. Am J Respir Crit Care Med 2020;202:193-201.
PubMed
20) Wang HE, et al. Trajectory of cognitive decline after sepsis. Crit Care Med 2021;49:1083-94.
PubMed
21) Iwashyna TJ, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010;304:1787-94.
PubMed
22) Sharshar T, et al. Science review:The brain in sepsis--culprit and victim. Crit Care 2005;9:37-44.
PubMed
23) Pandharipande PP, et al. Long-term cognitive impairment after critical illness. N Engl J Med 2014;370:185-6.
PubMed
24) Altman MT, et al. Sleep disturbance after hospitalization and critical illness:A systematic review. Ann Am Thorac Soc 2017;14:1457-68.
PubMed
25) Boede M, et al. Trajectories of depression in sepsis survivors:An observational cohort study. Crit Care 2021;25:161.
PubMed
26) Rousseau AF, et al. Bone metabolism and fracture risk during and after critical illness. Curr Opin Crit Care 2020;26:379-85.
PubMed
27) Ali Abdelhamid Y, et al. Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes:A systematic review and meta-analysis. Crit Care 2016;20:301.
PubMed
28) Van den Berghe G. On the neuroendocrinopathy of critical illness. Perspectives for feeding and novel treatments. Am J Respir Crit Care Med 2016;194:1337-48.
PubMed
29) Harlan EA, et al. Emotional experiences and coping strategies of family members of critically ill patients. Chest 2020;158:1464-72.
PubMed
30) Azoulay E, et al. Risk of post-traumatic stress symptoms in family members of intensive care unit patients. Am J Respir Crit Care Med 2005;171:987-94.
PubMed
31) Khandelwal N, et al. Prevalence, risk factors, and outcomes of financial stress in survivors of critical illness. Crit Care Med 2018;46:e530-9.
PubMed
32) Mikkelsen ME, et al. Society of critical care medicine's international consensus conference on prediction and identification of long-term impairments after critical illness. Crit Care Med 2020;48:1670-9.
PubMed
33) Pun BT, et al. Caring for critically ill patients with the ABCDEF bundle:Results of the ICU liberation collaborative in over 15, 000 adults. Crit Care Med 2019;47:3-14.
 
34) Morandi A, et al. Worldwide survey of the "Assessing pain, Both spontaneous awakening and breathing trials, Choice of drugs, Delirium monitoring/management, Early exercise/mobility, and Family empowerment" (ABCDEF)bundle. Crit Care Med 2017;45:e1111-22.
PubMed
35) 日本集中治療医学会Pics対策・生活の質改善検討委員会. 本邦の診療現場におけるpost-intensive care syndrome(PICS)の実態調査. 日集中医誌 2019;26:467-75.
 
36) Schweickert WD, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients:A randomised controlled trial. Lancet 2009;373:1874-82.
PubMed
37) 日本集中治療医学会早期リハビリテーション検討委員会. 集中治療における早期リハビリテーション-根拠に基づくエキスパートコンセンサス. 日集中医誌 2017;24:255-303.
 
38) Fuke R, et al. Early rehabilitation to prevent postintensive care syndrome in patients with critical illness:A systematic review and meta-analysis. BMJ Open 2018;8:e019998.
PubMed
39) Walsh TS, et al. Increased hospital-based physical rehabilitation and information provision after intensive care unit discharge:The RECOVER randomized clinical trial. JAMA Intern Med 2015;175:901-10.
PubMed
40) Fossat G, et al. Effect of in-bed leg cycling and electrical stimulation of the quadriceps on global muscle strength in critically ill adults:A randomized clinical trial. JAMA 2018;320:368-78.
PubMed
41) Nickels MR, et al. Effect of in-bed cycling on acute muscle wasting in critically ill adults:A randomised clinical trial. J Crit Care 2020;59:86-93.
PubMed
42) Kress JP, et al. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med 2003;168:1457-61.
 
43) Mehlhorn J, et al. Rehabilitation interventions for postintensive care syndrome:A systematic review. Crit Care Med 2014;42:1263-71.
PubMed
44) McPeake J, et al. Models of peer support to remediate post-intensive care syndrome:A report developed by the society of critical care medicine thrive international peer support collaborative. Crit Care Med 2019;47:e21-7.
 
45) Garrouste-Orgeas M, et al. Effect of an ICU Diary on Posttraumatic Stress Disorder Symptoms Among Patients Receiving Mechanical Ventilation:A Randomized Clinical Trial. JAMA 2019;322:229-39.
PubMed
46) Devlin JW, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018;46:e825-73.
PubMed
47) Brummel NE, et al. Feasibility and safety of early combined cognitive and physical therapy for critically ill medical and surgical patients:The Activity and Cognitive Therapy in ICU(ACT-ICU)trial. Intensive Care Med 2014;40:370-9.
 
48) Jackson JC, et al. Cognitive and physical rehabilitation of intensive care unit survivors:Results of the RETURN randomized controlled pilot investigation. Crit Care Med 2012;40:1088-97.
PubMed
49) Rosa RG, et al. Effect of flexible family visitation on delirium among patients in the intensive care unit:The ICU visits randomized clinical trial. JAMA 2019;322:216-28.
PubMed
50) Au SS, et al. Family participation in intensive care unit rounds:Comparing family and provider perspectives. J Crit Care 2017;38:132-6.
PubMed
51) Amass TH, et al. Family care rituals in the ICU to reduce symptoms of post-traumatic stress disorder in family members- A multicenter, multinational, before-and-after intervention trial. Crit Care Med 2020;48:176-84.
PubMed
52) Lautrette A, et al. A communication strategy and brochure for relatives of patients dying in the ICU. N Engl J Med 2007;356:469-78.
PubMed
53) Kentish-Barnes N, et al. Effect of a condolence letter on grief symptoms among relatives of patients who died in the ICU:A randomized clinical trial. Intensive Care Med 2017;43:473-84.
PubMed
54) Hopkins RO, et al. Physical therapy on the wards after early physical activity and mobility in the intensive care unit. Phys Ther 2012;92:1518-23.
PubMed
55) Ball C, et al. Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care:Non-randomised population based study. BMJ 2003;327:1014.
 
56) Hirshberg EL, et al. Impact of critical illness on resource utilization:A comparison of use in the year before and after ICU admission. Crit Care Med 2019;47:1497-504.
PubMed
57) Liu K, et al. ABCDEF bundle and supportive ICU practices for patients with coronavirus disease 2019 infection:An international point prevalence study. Crit Care Explor 2021;3:e0353.
PubMed
58) McWilliams D, et al. Rehabilitation levels in patients with COVID-19 admitted to intensive care requiring invasive ventilation. An observational study. Ann Am Thorac Soc 2021;18:122-9.
PubMed
59) Pun BT, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19(COVID-D):A multicentre cohort study. Lancet Respir Med 2021;9:239-50.
 
60) Martillo M, et al. Postintensive care syndrome in survivors of critical illness celated to Coronavirus disease 2019:Cohort study from a New York city critical care recovery clinic. Crit Care Med 2021;49:1427-38.
PubMed
61) Snell KP, et al. A novel approach to ICU survivor care:A population health quality improvement project. Crit Care Med 2020;48:e1164-70.
 
62) Haines KJ, et al. Enablers and barriers to implementing ICU follow-up clinics and peer support groups following critical illness:The thrive collaboratives. Crit Care Med 2019;47:1194-200.
PubMed
63) Eakin MN, et al. Association between participant contact attempts and reports of being bothered in a national, longitudinal cohort study of ARDS survivors. Chest 2020;158:588-95.
 
64) Cuthbertson BH, et al. The PRaCTICaL study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness:A pragmatic randomised controlled trial. BMJ 2009;339:b3723.
PubMed
65) Rosa RG, et al. More than the tip of the iceberg:Association between disabilities and inability to attend a clinic-based post-ICU follow-up and how it may impact on health inequalities. Intensive Care Med 2018;44:1352-4.
 
66) Taylor SP, et al. Association between adherence to recommended care and outcomes for adult survivors of sepsis. Ann Am Thorac Soc 2020;17:89-97.
PubMed
P.352 掲載の参考文献
1) McClave SA, et al;Society of Critical Care Medicine;American Society for Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient:Society of Critical Care Medicine (SCCM)and American Society for Parenteral and Enteral Nutrition(A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2016;40:159-211.
 
2) Singer P, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019;38:48-79.
PubMed
3) Sobotka L, Soeters PB. Basics in clinical nutrition:Metabolic response to injury and sepsis. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 2009;4:e1-3.
 
4) van Zanten ARH, et al. Nutrition therapy and critical illness:Practical guidance for the ICU, post-ICU, and long-term convalescence phases. Crit Care 2019;23:368.
PubMed
5) Reignier J, et al;Investigators N-T;group CRiICaSC. Enteral versus parenteral early nutrition in ventilated adults with shock:A randomised, controlled, multicentre, open-label, parallel-group study(NUTRIREA-2). Lancet 2018;391:133-43.
 
6) Renaudier M, et al. Acute mesenteric ischaemia in refractory shock on veno-arterial extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Care 2020;10:62-70.
PubMed
7) Poulard F, et al. Impact of not measuring residual gastric volume in mechanically ventilated patients receiving early enteral feeding:A prospective before-after study. JPEN J Parenter Enteral Nutr 2010;34:125-30.
 
8) Bartlett RH, et al. Measurement of metabolism in multiple organ failure. Surgery 1982;92:771-9.
PubMed
9) Casaer MP, et al. Role of disease and macronutrient dose in the randomized controlled EPaNIC trial:A post hoc analysis. Am J Respir Crit Care Med 2013;187:247-55.
 
10) Fiaccadori E, et al. ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clin Nutr 2021;40:1644-68.
PubMed
11) Patkova A, et al. Energy, Protein, Carbohydrate, and Lipid Intakes and Their Effects on Morbidity and Mortality in Critically Ill Adult Patients:A Systematic Review. Adv Nutr 2017;8:624-34.
PubMed
12) Du Bois EF. THE BASAL METABOLISM IN FEVER. JAMA 1921;77:352-7.
 
13) Mira JC, et al. Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome. Crit Care Med 2017;45:253-262.
PubMed
P.360 掲載の参考文献
1) Pastores SM, et al;Corticosteroid Guideline Task Force of SCCM and ESICM. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency(CIRCI)in Critically Ill Patients(Part II):Society of Critical Care Medicine(SCCM)and European Society of Intensive Care Medicine(ESICM)2017. Crit Care Med 2018;46:146-8.
PubMed
2) Annane D, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults:A systematic review. JAMA 2009;301:2362-75.
PubMed
3) Venkatesh B, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med 2018;378:797-808.
PubMed
4) Annane D, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 2018;378:809-18.
PubMed
5) Venkatesh B, et al. Evaluation of random plasma cortisol and the low dose corticotropin test as indicators of adrenal secretory capacity in critically ill patients:A prospective study. Anaesth Intensive Care 2005;33:201-9.
PubMed
6) Rhodes A, et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2016. Intensive Care Med 2017;43:304-77.
PubMed
7) NICE-SUGAR Study Investigators;Finfer S, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
 
8) COIITSS Study Investigators;Annane D, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults:A randomized controlled trial. JAMA 2010;303:341-8.
 
9) Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients:Risk factors and outcomes. Crit Care Med 2007;35:2262-7.
PubMed
10) Arabi YM, et al. Hypoglycemia with intensive insulin therapy in critically ill patients:Predisposing factors and association with mortality. Crit Care Med 2009;37:2536-44.
PubMed
11) Vriesendorp TM, et al. Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med 2006;34:96-101.
PubMed
12) Bellomo R, Egi M. What is a NICE-SUGAR for patients in the intensive care unit? Mayo Clin Proc 2009;84:400-2.
PubMed
13) Yatabe T, et al. The optimal target for acute glycemic control in critically ill patients:A network meta-analysis. Intensive Care Med 2017;43:16-28.
PubMed
14) Inoue S, et al. Accuracy of blood-glucose measurements using glucose meters and arterial blood gas analyzers in critically ill adult patients:Systematic review. Crit Care 2013;17:R48.
PubMed
P.373 掲載の参考文献
1) 今井孝祐. 集中治療医学の定義. 日集中医誌 2009;16:503-4.
 
2) 日本医療機能評価機構. 医療事故情報収集等事業第37回報告書. 平成26年.
 
3) 扶桑薬品工業株式会社. サブラッド(R)血液ろ過用補充液BSG 添付文書. 2017年10月改訂(第3版). TB_20171016094302_69.pdf(fuso-pharm.co.jp)[2022年11月26日閲覧]
 
4) 西田修, ほか. 急性血液浄化療法施行時の抗菌薬投与の基本的考え方. ICUとCCU 2013;12:929-37.
Medical*Online
5) 塚本達雄, ほか. 持続的血液浄化療法施行中の医療器具取り違えによる肝移植後患者死亡-事例報告と再発防止策. 日本急性血液浄化学会雑誌2013;4:148-53.
 
6) 高氏修平, ほか. 成人重症敗血症・敗血症ショックに対するV-A ECMOについての後ろ向き研究. 日救急医会誌 2017;28:904-9.
 
7) 一般社団法人日本集中治療医学会, ほか. 成人敗血症性ショック患者に対する補助循環の適応は? 日本版敗血症診療ガイドライン2020(J-SSCG2020). ダイジェスト版. 東京:真興交易医書出版部;2020. p.154-5.
 
8) 日本体外循環技術医学会安全対策委員会. 「補助循環の安全管理基準」に関するQ&A. 2017. http://jasect.umin.ac.jp/safety/pdf/hojyojyunkan-safetyQ&A.pdf[2022年11月26日閲覧]
 
9) Kilgannon JH, et al. Relationship Between Supranormal Oxygen Tension and Outcome After Resuscitation From Cardiac Arrest. Circulation 2011;14:2717-22.
 
10) 明石岩雄, ほか. ECMOにおける薬物動態の変化. INTENSIVIST 2021;12:360-5.
 
P.382 掲載の参考文献
1) 日本集中治療医学会早期リハビリテーション検討委員会. 集中治療における早期リハビリテーション-根拠に基づくエキスパートコンセンサス. 日集中医誌 2017;24:255-303.
 
2) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン 2020特別委員会. 日本版敗血症診療ガイドライン 2020(J-SSCG2020). 日集中医誌 2021;28 Suppl:S1-411.
 
3) Fan E, et al. An official American Thoracic Society Clinical Practice guideline:The diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med 2014;190:1437-46.
PubMed
4) Anekwe DE, et al. Early rehabilitation reduces the likelihood of developing intensive care unit-acquired weakness:A systematic review and meta-analysis. Physiotherapy 2020;107:1-10.
PubMed
5) Zayed Y, et al. Effects of neuromuscular electrical stimulation in critically ill patients:A systematic review and meta-analysis of randomised controlled trials. Aust Crit Care 2020;33:203-10.
PubMed
6) Takaoka A, et al. The Efficacy and Safety of In-Intensive Care Unit Leg-Cycle Ergometry in Critically Ill Adults. A Systematic Review and Meta-analysis. Ann Am Thorac Soc 2020;17:1289-1307.
PubMed
7) Segers J, et al. Feasibility of neuromuscular electrical stimulation in critically ill patients. J Crit Care 2014;29:1082-8.
PubMed
8) Poulsen JB, et al. Effect of transcutaneous electrical muscle stimulation on muscle volume in patients with septic shock. Crit Care Med 2011;39:456-61.
PubMed
9) Zang K, et al. The effect of early mobilization in critically ill patients:A meta-analysis. Nurs Crit Care 2020;25:360-7.
PubMed
10) Zhang L, et al. Early mobilization of critically ill patients in the intensive care unit:A systematic review and meta-analysis. PLoS One 2019;14:e0223185.
PubMed
11) Okada Y, et al. Early versus delayed mobilization for in-hospital mortality and health-related quality of life among critically ill patients:A systematic review and meta-analysis. J Intensive Care 2019;7:57.
 
12) Fuke R, et al. Early rehabilitation to prevent postintensive care syndrome in patients with critical illness:A systematic review and meta-analysis. BMJ Open 2018;8:e019998.
PubMed
13) Waldauf P, et al. Effects of Rehabilitation Interventions on Clinical Outcomes in Critically Ill Patients:Systematic Review and Meta-Analysis of Randomized Controlled Trials. Crit Care Med 2020;48:1055-65.
PubMed
14) Morri PE, et al. Standardized Rehabilitation and Hospital Length of Stay Among Patients With Acute Respiratory Failure:A Randomized Clinical Trial. JAMA 2016;315:2694-702.
 
15) Schaller SJ, et al. Early, goal-directed mobilisation in the surgical intensive care unit:A randomised controlled trial. Lancet 2016;388:1377-88.
PubMed
16) Pohlman MC, et al. Feasibility of physical and occupational therapy beginning from initiation of mechanical ventilation. Crit Care Med 2010;38:2089-94.
PubMed
17) Nakanishi N, et al. Monitoring of muscle mass in critically ill patients:Comparison of ultrasound and two bioelectrical impedance analysis devices. J Intensive Care 2019;7:61.
PubMed

5章 アドバンス : 敗血症管理の工夫

P.391 掲載の参考文献
1) Kaku M. [The 41st Scientific Meeting:perspectives of internal medicine;lessons from the disaster of the Great East Japan earthquake;3. Medical disease learned from the Great East Japan earthquake--feature, treatment and prevention-;5)Total management for infectious diseases]. Nihon Naika Gakkai Zasshi 2014;103:572-80.
PubMed
2) Tokuda K, et al. A survey conducted immediately after the 2011 Great East Japan Earthquake:Evaluation of infectious risks associated with sanitary conditions in evacuation centers. J Infect Chemother 2014;20:498-501.
PubMed
3) Aoyagi T, et al. Characteristics of infectious diseases in hospitalized patients during the early phase after the 2011 great East Japan earthquake:Pneumonia as a significant reason for hospital care. Chest 2013;143:349-56.
PubMed
4) Saito A, et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother 2006;12:63-9.
PubMed
5) Akama T, et al. Whole Genome Tiling Array Analysis of Bacterial Genome. In:Campbell MJ, ed. DNA Microarrays, Synthesis and Synthetic DNA. Hauppauge, NY:Nova Science Publishers;2012. p.301-15.
 
6) 畠山祐司, ほか. Scedosporium属が分離された津波肺の3症例. 日臨微誌 2012;22:289-97.
 
7) Nnadi NE, Carter DA. Climate change and the emergence of fungal pathogens. PLoS Pathog 2021;17:e1009503.
PubMed
8) Neblett Fanfair R, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med 2012;367:2214-25.
PubMed
9) Liang JL, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States:Recommendations of the Advisory Committee on Immunization Practices(ACIP). MMWR Recomm Rep 2018;67:1-44.
PubMed
10) Lin PC, et al. Epidemiological characteristics of lower extremity cellulitis after a typhoon flood. PLoS One 2013;8:e65655.
PubMed
11) 農林水産省. 監視伝染病の発生状況. 令和3年. https://www.maff.go.jp/j/syouan/douei/kansi_densen/kansi_densen.html[最終閲覧日2022年9月6日]
 
12) 国立感染症研究所. レプトスピラ症. IASR Vol. 42 p.103-5:2016年6月号. https://www.niid.go.jp/niid/ja/leptospirosis-m/leptospirosis-iasrtpc/6518-436t.html[最終閲覧日2022年9月6日]
 
13) Tanaka H, et al[. Isolation of Neisseria meningitidis from healthy persons in Japan]. Kansenshogaku Zasshi 2005;79:527-33.
PubMed
14) Chang YL, et al. New facets of antifungal therapy. Virulence 2017;8:222-36.
PubMed
15) Cornely OA, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014;20 Suppl 3:5-26.
 
16) Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol 2015;387:65-97.
PubMed
P.396 掲載の参考文献
1) Rudd KE, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017:Analysis for the Global Burden of Disease Study. Lancet 2020;395:200-11.
PubMed
2) Imaeda T, et al. Trends in the incidence and outcome of sepsis using data from a Japanese nationwide medical claim database-the Japan Sepsis Alliance(JaSA)study group. Crit Care 2021;25:338.
 
3) Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:801-10.
PubMed
4) Evans L, et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021;49:e1063-143.
PubMed
5) Seymour CW, et al. Assessment of clinical criterial for sepsis:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3). JAMA 2016;315:762-74.
 
6) Fernando SM, et al. Prognostic accuracy of the quick sequential organ failure assessment for mortality in patients with suspected infection:A systematic review and meta-analysis. Ann Intern Med 2018;169:266-75.
 
7) Serafim R, et al. A comparison of the Quick-SOFA and systemic inflammatory response syndrome criteria for the diagnosis of sepsis and prediction of mortality:A systematic review and meta-analysis. Chest 2018;153:646-55.
 
8) Herwanto V, et al. Accuracy of Quick Sequential Organ Failure Assessment score to predict sepsis mortality in 121 studies including 1, 716, 017 individuals:A systemic review and meta-analysis. Crit Care Explor 2019;1:e0043.
PubMed
9) Liu VX, et al. Comparison of early warning scoring systems for hospitalized patients with and without infection at risk for in-hospital mortality and transfer to the intensive care unit. JAMA Netwk Open 2020;3:e205191.
 
10) National Early Warning Score(NEWS)2. https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2 [2022年9月5日アクセス]
 
11) Churpek MM, et al. Investigating the impact of different suspicion of infection criteria on the accuracy of quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores. Crit Care Med 2017;45:1805-12.
PubMed
12) Giacobbe DR, et al. Early detection of sepsis with machine learning techniques:A brief clinical perspective. Front Med(Lausanne)2021;8:617486.
PubMed
13) Delahanty RJ, et al. Development and evaluation of a machine learning model for the early identification of patients at risk of sepsis. Ann Emerg Med 2019;73:334-44.
PubMed
P.405 掲載の参考文献
1) Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002;19:349-53.
 
2) Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42:S35-9.
PubMed
3) Pais GM, et al. Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury. Antimicrob Agents Chemother 2019;63:e00079-19.
PubMed
4) Avedissian SN, et al. Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother 2019;74:2326-34.
 
5) Tsutsuura M, et al. The monitoring of vancomycin:A systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis 2021;21:153.
PubMed
6) Yanagihara K, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012:General view of the pathogens' antibacterial susceptibility. J Infect Chemother 2017;23:587-97.
PubMed
7) Takesue Y, et al. Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan:Comparison of data from nationwide surveillance studies conducted in 2010 and 2014-2015. J Infect Chemother 2017;23:339-48.
 
8) Hanaki H, et al, Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011. J Infect Chemother 2014;20:527-34.
PubMed
9) Gawronski KM, et al. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther 2013;35:772-9.
 
10) Matsumoto K, et al. Practice guidelines for therapeutic drug monitoring of vancomycin:A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 2013;19:365-80.
 
11) Ye ZK, et al. Therapeutic drug monitoring of vancomycin:A guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother 2016;71:3020-5.
 
12) Clark L, et al. Examining the Relationship between Vancomycin Area under the Concentration Time Curve and Serum Trough Levels in Adults with Presumed or Documented Staphylococcal Infections. Ther Drug Monit 2019;41:483-8.
PubMed
13) Kamel AB, et al. Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients. Ther Drug Monit 2017;39:83-7.
 
14) Pai MP, et al. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 2014;77:50-7.
PubMed
15) Neely MN, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014;58:309-16.
PubMed
16) Oda K, et al. Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application. Pharm Res 2021;38:637-46.
PubMed
17) Shime N, et al. The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 2010;29:1475-9.
PubMed
18) Lodise TP, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections:How much is enough? Clin Infect Dis 2014;59:666-75.
PubMed
19) Casapao AM, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 2015;59:2978-85.
PubMed
20) Lodise TP, et al. The Emperor's New Clothes:Prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant staphylococcus aureus bloodstream infections(PROVIDE). Clin Infect Dis 2020;70:1536-45.
PubMed
21) Oda K, et al. Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy. Pharm Res 2020;37:108.
PubMed
22) Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479-501.
 
23) Watanabe E, et al. Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model. J Glob Antimicrob Resist 2020;24:83-7.
 
24) Hanai Y, et al. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection:A systematic review and meta-analysis. J Clin Pharm Ther 2021;46:622-32.
PubMed
25) Ueda T, et al. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20μg/mL using a regimen of 12mg/kg for five doses within the initial 3 days. BMC Pharmacol Toxicol 2020;21:50.
 
26) Byrne CJ, et al. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J Antimicrob Chemother 2018;73:995-1003.
PubMed
27) 中山貴美子, ほか. 成人におけるteicoplaninの母集団薬物動態解析. 日本化学療法学会雑誌 2006;54:1-6.
 
28) Moore RD, et al. Clinical response to aminoglycoside therapy:Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
PubMed
29) Sato R, et al. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:3763-9.
PubMed
30) Yamada T, et al. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother 2021;27:256-61.
 
31) Oda K, et al. Evaluation of once-daily dosing and target concentrations in therapeutic drug monitoring for arbekacin:A meta-analysis. J Infect Chemother 2021;27:26-31.
PubMed
32) Andes D, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:3165-9.
 
33) Hanai Y, et al. Favorable Effects of Voriconazole Trough Concentrations Exceeding 1μg/mL on Treatment Success and All-Cause Mortality:A Systematic Review and Meta-Analysis. J Fungi(Basel)2021;7:306.
 
34) Cota JM, et al. Antifungal dose adjustment in renal and hepatic dysfunction:Pharmacokinetic and pharmacodynamic considerations. Current Fungal Infection Reports 2010;4:120-8.
 
35) Yamada T, et al. Necessity for a significant maintenance dosage reduction of voriconazole in patients with severe liver cirrhosis(Child-Pugh Class C). Biol Pharm Bull 2018;41:1112-8.
 
36) Hamada Y, et al. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms:A multicentre study conducted in Japan. Mycoses 2020;63:779-86.
 
P.417 掲載の参考文献
1) Sonneville R, et al. Understanding brain dysfunction in sepsis. Ann Intensive Care 2013;3:15.
PubMed
2) Oddo M, Taccone FS. How to monitor the brain in septic patients ? Minerva Anestesiol 2015;81:776-88.
PubMed
3) Iacobone E, et al. Sepsis-associated encephalopathy and its differential diagnosis. Crit Care Med 2009;37:S331-6.
PubMed
4) Gofton TE, Young GB. Sepsis-associated encephalopathy. Nat Rev Neurol 2012;8:557-66.
PubMed
5) Heming N, et al. Neuroanatomy of sepsis-associated encephalopathy. Crit Care 2017;21:65.
PubMed
6) Polito A, et al. Pattern of brain injury in the acute setting of human septic shock. Crit Care 2013;17:R204.
PubMed
7) Bolton CF, Young GB. Managing the nervous system effects of sepsis. Chest 2007;131:1273-4.
PubMed
8) Schramm P, et al. Impaired cerebrovascular autoregulation in patients with severe sepsis and sepsis-associated delirium. Crit Care 2012;16:R181.
PubMed
9) Ely EW, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;291:1753-62.
PubMed
10) Salluh JI, et al. Delirium epidemiology in critical care(DECCA):An international study. Crit Care 2010;14:R210.
 
11) Zhang LN, et al. Epidemiological features and risk factors of sepsis-associated encephalopathy in intensive care unit patients:2008-2011. Chin Med J 2012;125:828-31.
PubMed
12) Young GB, et al. The encephalopathy associated with septic illness. Clin Investig Med 1990;13:297-304.
 
13) Bolton CF, et al. The neurological complications of sepsis. Ann Neurol 1993;33:94-100.
PubMed
14) Semmler A, et al. Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. J Neurol Neurosurg Psychiatry 2013;84:62-9.
PubMed
15) Sonneville R, et al. Potentially modifiable factors contributing to sepsis-associated encephalopathy. Intensive Care Med 2017;43:1075-84.
PubMed
16) Prescott HC. Variation in Postsepsis Readmission Patterns:A Cohort Study of Veterans Affairs Beneficiaries. Ann Am Thorac Soc 2017;14:230-7.
PubMed
17) Iwashyna TJ, Speelmon EC. Advancing a Third Revolution in Critical Care. Am J Respir Crit Care Med 2016;194:782-3.
PubMed
18) Kaukonen KM, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16.
PubMed
19) Iwashyna TJ, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010;304:1787-94.
PubMed
20) Douglas VC, Josephson SA. Altered mental status. Continuum(Minneap Minn)2011;17:967-83.
PubMed
21) Miu DK, Yeung JC. Incidence of post-stroke delirium and 1-year outcome. Geriatr Gerontol Int 2013;13:123-9.
PubMed
22) Ely EW, et al. Evaluation of delirium in critically ill patients:Validation of the Confusion Assessment Method for the Intensive Care Unit(CAM-ICU). Crit Care Med 2001;29:1370-9.
PubMed
23) Bergeron N, et al. Intensive Care Delirium Screening Checklist:Evaluation of a new screening tool. Intensive Care Med 2001;27:859-64.
PubMed
24) Luetz A, et al. Different assessment tools for intensive care unit delirium:Which score to use? Crit Care Med 2010;38:409-18.
PubMed
25) Reade MC, et al. Routine use of the Confusion Assessment Method for the Intensive Care Unit(CAM-ICU)by bedside nurses may underdiagnose delirium. Crit Care Resusc 2011;13:217-24.
PubMed
26) van Eijk MM, et al. Routine use of the confusion assessment method for the intensive care unit:A multicenter study. Am J Respir Crit Care Med 2011;184:340-4.
PubMed
27) Tomasi CD, et al. Comparison of CAM-ICU and ICDSC for the detection of delirium in critically ill patients focusing on relevant clinical outcomes. J Crit Care 2012;27:212-7.
PubMed
28) Eidelman LA, et al. The spectrum of septic encephalopathy. Definitions, etiologies, and mortalities. JAMA 1996;275:470-3.
PubMed
29) Wijdicks EF, et al Validation of a new coma scale:The FOUR score. Ann Neurol 2005;58:585-93.
PubMed
30) Luetz A, et al. Delirium, sedation and analgesia in the intensive care unit:A multinational, two-part survey among intensivists. PLoS ONE 2014;9:e110935.
PubMed
31) Young GB, et al. The electroencephalogram in sepsis-associated encephalopathy. J Clin Neurophysiol 1992;9:145-52.
PubMed
32) Osuchowski MF, et al. Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS):An International Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis. Shock 2018;50:377-80.
 
33) Azabou E, et al. Early Standard Electroencephalogram Abnormalities Predict Mortality in Septic Intensive Care Unit Patients. PLoS ONE 2015;10:e0139969.
PubMed
34) Blume WT. Drug effects on EEG. J Clin Neurophysiol 2006;23:306-11.
PubMed
35) Kaplan PW. The EEG in metabolic encephalopathy and coma. J Clin Neurophysiol 2004;21:307-18.
 
36) Luitse MJ, et al. Deep coma and diffuse white matter abnormalities caused by sepsis-associated encephalopathy. Lancet 2013;381:2222.
PubMed
37) Sharshar T, et al. Brain lesions in septic shock:A magnetic resonance imaging study. Intensive Care Med 2007;33:798-806.
PubMed
38) Ahmed M, et al. Magnetic resonance imaging findings in a fatal case of Salmonella typhi-associated encephalopathy:A case report and literature review. Neurol India 2011;59:270-2.
 
39) Gunther ML, et al. The association between brain volumes, delirium duration, and cognitive outcomes in intensive care unit survivors:The VISIONS cohort magnetic resonance imaging study. Crit Care Med 2012;40:2022-32.
PubMed
40) Pierrakos C, Vincent JL. Sepsis biomarkers:A review. Crit Care 2010;14:R15.
PubMed
41) Nguyen DN, et al. Elevated serum levels of S-100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. Crit Care Med 2006;34:1967-74.
PubMed
42) Anderson BJ, et al. Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis. J Crit Care 2016;36:18-23.
PubMed
43) Ehler J, et al. The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy-A prospective, pilot observational study. PLoS ONE 2019;14:e0211184.
PubMed
44) Shahim P, et al. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 2017;88:1788-94.
PubMed
45) Lu CH, et al. Neurofilament light chain:A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247-57.
 
46) Kuhle J, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 2017;88:826-31.
 
47) Peterson EC, et al. Regulation of cerebral blood flow. Int J Vasc Med 2011;2011:823525.
PubMed
48) Taccone FS, et al. Cerebral microcirculation is impaired during sepsis:An experimental study. Crit Care 2010;14:R140.
PubMed
49) Taccone FS, et al. Sepsis is associated with altered cerebral microcirculation and tissue hypoxia in experimental peritonitis. Crit Care Med 2014;42:e114-22.
PubMed
50) Berg RM, et al. Disassociation of static and dynamic cerebral autoregulatory performance in healthy volunteers after lipopolysaccharide infusion and in patients with sepsis. Am J Physiol Regul Integr Comp Physiol 2012;303:R1127-35.
PubMed
51) Pierrakos C, et al. Transcranial Doppler to assess sepsis-associated encephalopathy in critically ill patients. BMC Anesthesiol 2014;14:45.
PubMed
52) Pfister D, et al. Cerebral perfusion in sepsis-associated delirium Crit Care 2008;12:R63.
PubMed
53) Berg RMG, et al. Dynamic cerebral autoregulation to induced blood pressure changes in human experimental and clinical sepsis. Clin Physiol Funct Imaging 2015;36:490-6.
PubMed
54) Matta BF, Stow PJ. Sepsis-induced vasoparalysis does not involve the cerebral vasculature:Indirect evidence from autoregulation and carbon dioxide reactivity studies. Br J Anaesth 1996;76:790-4.
 
55) Taccone FS, et al. Cerebral autoregulation is influenced by carbon dioxide levels in patients with septic shock. Neurocrit Care 2010;12:35-42.
PubMed
56) Crippa IA, et al. Impaired cerebral autoregulation is associated with brain dysfunction in patients with sepsis. Crit Care 2018;22:327.
PubMed
57) Dellinger RP, et al. Surviving Sepsis Campaign:International guidelines for management of severe sepsis and septic shock:2008. Intensive Care Med 2008;34:17-60.
PubMed
58) Barr J, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013;41:263-306.
PubMed
59) Campbell N, et al. The cognitive impact of anticholinergics:A clinical review. Clin Interv Aging 2009;4:225-33.
PubMed
60) Young GB, Doig GS. Continuous EEG monitoring in comatose intensive care patients:Epileptiform activity in etiologically distinct groups. Neurocrit Care 2005;2:5-10.
PubMed
61) Schweickert WD, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients:A randomised controlled trial. Lancet 2009;373:1874-82.
PubMed
62) Brummel NE, et al. Feasibility and safety of early combined cognitive and physical therapy for critically ill medical and surgical patients:The Activity and Cognitive Therapy in ICU(ACT-ICU)trial. Intensive Care Med 2014;40:370-9.
 
63) Ke L, et al. Non-pharmacological Treatment of Intensive Care Unit Delirium. Am J Nurs Sci 2019;8:119-28.
 
64) Tokuda Y, et al. Pupillary evaluation for differential diagnosis of coma. Postgrad Med J 2003;79:49-51.
PubMed
65) Claassen J, et al. Recommendations on the use of EEG monitoring in critically ill patients:Consensus statement from the neurointensive care section of the ESICM. Intensive Care Med 2013;39:1337-51.
 
66) van de Beek D, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351:1849-59.
PubMed
67) Angstwurm K, et al. Isolated bacterial meningitis as the key syndrome of infective endocarditis. Infection 2004;32:47-50.
PubMed
68) Kanakadandi V, et al. The Austrian syndrome:A case report and review of the literature. Infection 2013;41:695-700.
PubMed
69) Lucas MJ, et al. Endocarditis in adults with bacterial meningitis. Circulation 2013;127:2056-62.
PubMed
P.429 掲載の参考文献
1) 志賀 隆, ほか監修, 則末泰博, ほか編. 必勝!気道管理術ABCははずさない. 東京:学研メディカル秀潤社;2015.
 
2) Ebihara S, et al. Mechanical ventilation protects against diaphragm injury in sepsis:Interaction of oxidative and mechanical stresses. Am J Respir Crit Care Med 2002;165:221-8.
PubMed
3) Hussain SNA, Roussos C. Distribution of respiratory muscle and organ blood flow during endotoxic shock in dogs. J Appl Physiol 1985;59:1802-8.
 
4) Tuchschmidt J, et al. Oxygen consumption in sepsis and septic shock. Crit Care Med 1991;19:664-71.
 
5) Chittock DR, et al. Oxygen delivery and consumption during sepsis. Clin Chest Med 1996;17:263-78.
PubMed
6) Manthous CA, et al. The effect of mechanical ventilation on oxygen consumption in critically ill patients. Am J Respir Crit Care Med 1995;151:210-4.
PubMed
7) Rhodes A, et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2016. Crit Care Med 2017;45:304-77.
 
8) Rojas M, et al. Endotoxin-induced lung injury in mice:Structural, functional, and biochemical responses. Am J Physiol - Lung Cell Mol Physiol 2005;288:333-41.
 
9) Zampieri FG, et al. Mechanical ventilation in sepsis:A reappraisal. Shock 2017;47:41-6.
PubMed
10) Sevransky JE, et al. Mechanical ventilation in sepsis-induced acute lung injury/acute respiratory distress syndrome:An evidence-based review. Crit Care Med 2004;32:S548-53.
PubMed
11) Neto AS, et al. Lung-protective ventilation with low tidal volumes and the occurrence of pulmonary complications in patients without acute respiratory distress syndrome:A systematic review and individual patient data analysis. Crit Care Med 2015;43:2155-63.
PubMed
12) Determann RM, et al. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury:A preventive randomized controlled trial. Crit Care 2010;14:1-14.
PubMed
13) Neto AS, et al. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT):An international, multicentre, prospective study. Lancet Respir Med 2016;4:882-93.
PubMed
14) Simonis FD, et al. Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS:A Randomized Clinical Trial. JAMA - J Am Med Assoc 2018;320:1872-80.
 
15) Yoshida T, et al. Esophageal manometry and regional transpulmonary pressure in lung injury. Am J Respir Crit Care Med 2018;197:1018-26.
PubMed
16) Esteban A, et al. A Comparison of Four Methods of Weaning Patients from Mechanical Ventilation. N Engl J Med 1995;332:345-50.
 
17) Hoste EA, et al. Four phases of intravenous fluid therapy:A conceptual model. Br J Anaesth 2014;113:740-7.
PubMed
18) Rochwerg B, et al. Official ERS/ATS clinical practice guidelines:Noninvasive ventilation for acute respiratory failure. Eur Respir J 2017;50:1602426.
PubMed
19) Esteban A, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med 2004;350:2452-60.
PubMed
20) Keenan SP, et al. Noninvasive positive-pressure ventilation for postextubation respiratory distress:A randomized controlled trial. JAMA 2002;287:3238-44.
PubMed
P.438 掲載の参考文献
1) 日本集中治療医学会・日本救急医学会合同;日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020. 日集中医誌 2021;28:S1-414. https://www.jsicm.org/pdf/jjsicm28Suppl.pdf
 
2) de Montmollin E, et al. Bench-to-bedside review:Beta-adrenergic modulation in sepsis. Crit Care 2009;13:230.
PubMed
3) Parker MM, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984;100:483-90.
PubMed
4) Vieillard-Baron A. Septic cardiomyopathy. Ann Intensive Care 2011;1:6.
PubMed
5) Heubach JF, et al. Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. Mol Pharmacol 2004;65:1313-22.
 
6) Lyon AR, et al. Stress(Takotsubo)cardiomyopathy--a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008;5:22-9.
PubMed
7) Suzuki T, et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005;33:2294-301.
PubMed
8) Hagiwara S, et al. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock 2009;31:515-20.
 
9) Kimmoun A, et al. β1-Adrenergic Inhibition Improves Cardiac and Vascular Function in Experimental Septic Shock. Crit Care Med 2015;43:e332-40.
 
10) Schmittinger CA, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008;12:R99.
PubMed
11) Morelli A, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock:A pilot study. Crit Care Med 2013;41:2162-8.
PubMed
12) J-Land 3S Study Group. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S):A multicentre, open-label, randomised controlled trial. Lancet Respir Med 2020;8:863-72.
 
13) Hasegawa D, et al. Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation:A Systematic Review and Meta-analysis of Randomized Controlled Trials. Chest 2021;159:2289-300.
 
14) Geri G, et al. Cardiovascular clusters in septic shock combining clinical and echocardiographic parameters:A post hoc analysis. Intensive Care Med 2019;45:657-67.
PubMed
15) Bristow MR, et al. Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium:Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
PubMed
P.440 掲載の参考文献
1 : 西田修,森山和広. 日内会誌 2021;110:942-8.
 
2 : Levey AS,et al. Kidney Int 2020;97:1117-29.
PubMed
P.441 掲載の参考文献
1 : Kellum JA, et al. Kidney Int Suppl 2012;2:1-138.
 
2 : AKI(急性腎障害)診療ガイドライン作成委員会, 編. 日腎会誌 2017;59:419-533.
 
3 : 令和4年3月4日 保医発0304 第1号
 
P.443 掲載の参考文献
1 : Gabarin RS, et al. J Innate Immun 2021;13:323-32.
PubMed
P.446 掲載の参考文献
1 : Dellinger RP, et al. JAMA 2018;320:1455-63.
PubMed
P.448 掲載の参考文献
1 : Zarbock A, et al. JAMA 2016;315:2190-9.
PubMed
2 : Gaudry S, et al. N Engl J Med 2016;375:122-33.
PubMed
3 : Barbar SD, et al. N Engl J Med 2018;379:1431-42.
PubMed
4 : Bagshaw SM, et al. N Engl J Med 2020;383:240-51.
PubMed
5 : Gaudry S, et al. Lancet 2021;397:1293-300.
PubMed
P.449 掲載の参考文献
1 : Silversides JA,et al. Crit Care Med 2018;46:1600-7.
PubMed
2 : Malbrain ML,et al. Anaesthesiol Intensive Ther 2014;46:361-80.
PubMed
P.450 掲載の参考文献
1 : Haase M, et al. Nat Rev Nephrol 2012;8:735-9.
PubMed
2 : Peters E, et al. Critical Care 2018;22:188.
PubMed
P.452 掲載の参考文献
1) 平澤博之. 重症敗血症/敗血症性ショックの今日的病態生理と持続血液濾過透析(CHDF)によるその制御. 日救急医会誌 2011;22:85-116.
 
2) 西田 修, 森山和広. Critical Care Nephrology-敗血症性急性腎障害の病態と管理. 日内会誌 2021;110:942-8.
 
3) 森山和広, 西田 修. 血液浄化器の種類と特徴. 救急・集中治療 2020;32:371-8.
Medical*Online
4) 森山和広, 西田 修. AKIに対する血液浄化法の考え方. 森松博史, 編. 重症患者における急性肝不全・急性腎傷害・代謝異常. 東京:中山書店;2018. p.130-41,
 
5) 森山和広, 西田 修. 血液浄化膜の種類と特徴. 腎臓内科 2021;14:98.
 
6) 平澤博之. PMX-DHP を再考する-敗血症の今日的病態生理におけるエンドトキシンの位置づけとPMX-DHPの意義. ICUとCCU 2020;44:541-8.
 
7) Moriyama K, Nishida O. Targeting cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns in sepsis via blood purification. Int J Mol Sci 2021;22:8882.
PubMed
8) 森山和広, 西田 修. 敗血症の病態生理と臓器障害進展のメカニズム. 麻酔 2020;69:716-23.
Medical*Online
9) 森山和広, 西田 修. 敗血症に対する急性血液浄化法(濾過・透析・吸着)の新たなる展開とは? 救急・集中治療 2017;29:431-8.
Medical*Online
10) 森山和広, ほか. 基礎的な見地からみた血中エンドトキシン除去の意義. 日急性血浄化会誌 2020;11:9-16.
Medical*Online
11) 森山和広, 西田 修. 敗血症に対する免疫制御血液浄化システム. ICUとCCU 2019;43:49-57.
Medical*Online
12) 森山和広, 西田 修. HMGB1制御は有望な治療手段である. 救急集中治療 2016;28:183-7.
 
13) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020 特別委員会. 日本版敗血症診療ガイドライン2020(J-SSCG2020). 日集中医誌 2021;28:S1-411.
 
14) Yumoto M, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial 2011;15:385-93.
PubMed
15) Moriyama K, et al. Involvement of ionic interactions in cytokine adsorption of polyethyleneimine-coated polyacrylonitrile and polymethyl methacrylate membranes in vitro. J Artif Organs 2020;23:240-6.
PubMed
16) Nakamura T, et al. Adsorption kinetics for high mobility group box 1 (HMGB1)protein in a polyacrylonitrile hemofiltration membrane. Ther Apher Dial 2020;25:66-72.
 
17) 山下千鶴, ほか. PMX-DHPを再考する-当院ICUにおける敗血症に対する血液浄化法治療戦略とPMX-DHPの位置づけ. ICUとCCU 2020;44:561-6.
 
18) Yamashita C, et al. In vitro study of endotoxin adsorption by a polymyxin B-immobilized fiber column. Blood Purif 2018;46:269-73.
PubMed
19) Ostermann M, et al. Patient selection and timing of continuous renal replacement therapy. Blood Purif 2016;42:224-37.
PubMed
20) Malbrain MLNG, et al. Principles of fluid management and stewardship in septic shock:It is time to consider the four D's and the four phases of fluid therapy. Ann Intensive Care 2018;8:66.
 
21) Murugan R, et al. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration:A secondary analysis of the Randomized Evaluation of Normal vs Augmented Level(RENAL)of renal replacement therapy trial. JAMA Netw Open 2019;2:e195418.
PubMed
P.464 掲載の参考文献
1) Vandewalle J, Libert C. Glucocorticoids in Sepsis:To Be or Not to Be. Front Immunol 2020;11:1318.
 
2) Annane D, et al. Critical illness-related corticosteroid insufficiency(CIRCI):A narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM)and the European Society of Intensive Care Medicine(ESICM). Intensive Care Med 2017;43:1781-92.
 
3) Nenke MA, et al. Depletion of high-affinity corticosteroid-binding globulin corresponds to illness severity in sepsis and septic shock;Clinical implications. Clin Endocrinol 2015;82:801-7.
PubMed
4) Liu B, et al. The Glucocorticoid Receptor in Cardiovascular Health and Disease. Cells 2019;8:1227.
PubMed
5) Annane D, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency(CIRCI)in critically ill patients(Part I):Society of Critical Care Medicine(SCCM)and European Society of Intensive Care Medicine(ESICM) 2017. Intensive Care Med 2017;43:1751-63.
PubMed
6) Marik PE, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients:Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008;36:1937-49.
PubMed
7) Annane D, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults:A systematic review. JAMA 2009;301:2362-75.
PubMed
8) Venkatesh B, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med 2018;378:797-808.
PubMed
9) Annane D, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 2018;378:809-18.
PubMed
10) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020(J-SSCG2020). 日集中医誌2021;28:S1-411.
 
11) Rhodes A, et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2016. Intensive Care Med 2017;43:304-77.
PubMed
12) Evans L, et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021:49;e1063-143.
PubMed
13) Annane D, et al. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock. JAMA 2002;288:862-71.
PubMed
14) Sprung CL, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
PubMed
15) COIITSS Study Investigators;Annane D, et al. Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults:A Randomized Controlled Trial. JAMA 2010;303:341-8.
 
16) 片岡 惇. JSEPTIC簡単アンケート. 第29回:敗血症性ショックに対するステロイド・酸素療法. Intensivist 2018;10:1036-41.
 
17) Yu TJ, et al. Comparing hydrocortisone and methylprednisolone in patients with septic shock. Adv Ther 2009;26:728-35.
PubMed
18) Ibarra-Estrada MA, et al. Timing, method and discontinuation of hydrocortisone administration for septic shock patients. World J Crit Care Med 2017;6:65-73.
PubMed
19) Tilouche N, et al. Comparison Between Continuous and Intermittent Administration of Hydrocortisone During Septic Shock:A Randomized Controlled Clinical Trial. Shock 2019;52:481-6.
PubMed
20) Hoang H, et al. Evaluation of Hydrocortisone Continuous Infusion Versus Intermittent Boluses in Resolution of Septic Shock. P T 2017;42:252-5.
PubMed
21) Huh JW, et al. Low-dose hydrocortisone treatment for patients with septic shock:A pilot study comparing 3 days with 7 days. Respirology 2011;16:1088-95.
 
22) Fujii T, et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock:The VITAMINS Randomized Clinical Trial. JAMA 2020;323:423-31.
PubMed
23) Sevransky JE, et al. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilatorand Vasopressor-Free Days in Patients With Sepsis:The VICTAS Randomized Clinical Trial. JAMA 2021;325:742-50.
PubMed
24) Iglesias J, et al. Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis:The ORANGES Trial. Chest 2020;158:164-73.
PubMed
P.473 掲載の参考文献
1) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会. 日本版重症患者の栄養療法ガイドライン. 日集中医誌 2016;23:185-281.
 
2) McClave SA, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient:Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition(A.S.P.E.N). JPEN 2017;40:159-211.
 
3) Canadian Clinical Practice Guidelines 2021 Summary of Topics and Recommendations. http://www.criticalcarenutrition.com/
 
4) Singer P, et al. ESPEN Guidelines on clinical nutrition in the intensive care unit. Clin Nutr 2019;38:48-79.
PubMed
5) Saha S, et al. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology 2021;160:1961-9.
PubMed
6) Al Harbi SA, et al. Association between phosphate disturbances and mortality among critically ill patients with sepsis or septic shock. BMC Pharmacol Toxicol 2021;22:30.
PubMed
7) Martindale R, et al. Nutrition Therapy in Critically Ill Patients With Coronavirus Disease 2019. JPEN J Parenter Enteral Nutr 2020;44:1174-84.
PubMed
8) Barazzoni R, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-Cov-2 infection. Clin Nutr 2020;39:1631-8.
PubMed
9) Bear D, et al. Critical care specialist group of the BDA guidance on management of nutrition and dietetic services during the COVID-19 pandemic. Critical care specialist group for the British dietetic association ver2.1.11 May 2020.
 
P.481 掲載の参考文献
1) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020. 日集中医誌 2021;28:S1-411.
 
2) 日本集中治療医学会・日本救急医学会合同:日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン2020. 日救急医会誌 2021;32:S1-411.
 
3) Obi J, et al. Treating sepsis with vitamin C, thiamine, and hydrocortisone:Exploring the quest for the magic elixir. J Crit Care 2020;57:231-9.
PubMed
4) Scholz SS, et al. Mortality in septic patients treated with vitamin C:A systematic meta-analysis. Crit Care 2021;25:17.
PubMed
5) Sevransky JE, et al. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilatorand Vasopressor-Free Days in Patients With Sepsis:The VICTAS Randomized Clinical Trial. JAMA 2021;325:742-50.
PubMed
6) Lamontagne F, et al. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. N Engl J Med 2022;386:2387-98.
PubMed
7) Reijven PLM, et al. Vitamin D:A magic bullet or a myth? Clin Nutr 2020;39:2663-74.
 
8) Quraishi SA, et al. Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis:A Randomized, Placebo-Controlled Trial. Crit Care Med 2015;43:1928-37.
PubMed
9) Leaf DE, et al. Randomized controlled trial of calcitriol in severe sepsis. Am J Respir Crit Care Med 2014;190:533-41.
PubMed

書評

最近チェックした商品履歴

Loading...